Articoli di riviste: "547.057 26"

1

Castro, Selma Barros Daltro de, José Wellington Marinho Aragão, Solange Mary Moreira Santos e Ivonete Barreto de Amorim. "O CONTEXTO DO CME EM FEIRA DE SANTANA: REVELANDO AS INTERSEÇÕES ENTRE O CENÁRIO NACIONAL E LOCAL". Interfaces Científicas - Educação 7, n. 3 (17 aprile 2019): 9–26. http://dx.doi.org/10.17564/2316-3828.2019v7n3p9-26.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

Abstract (sommario):

A origem dos CME no Brasil tem relação direta com acontecimentos políticos e sociais de caráter mundial, nacional e local, o que exige considerar as relações existentes entre contexto nacional e local. O presente artigo problematizou a criação do Conselho Municipal de Educação, apresentando as relações existentes entre os contextos nacional e local. Para tanto, objetivou 1) contextualizar o surgimento do CME no contexto brasileiro, 2)analisar a criação do Conselho Municipal de Educação de Feira de Santana até o ano de 1996, apresentando as relações políticas estabelecidas no contexto nacional e local. A discussão teórica amparou-se em Ball e Mainardes ( 2011) Castro (2016). Saviani (1988, 2008, 2010), Souza ( 2006, 2013). A opção teórico-metodológica de pesquisa teve inspiração na abordagem do ciclo de políticas.Como estratégias metodológicas foram feitas a análise de documentos oficiais do município de Feira de Santana, a saber Leis Municipais n. 037/90, n.1 477/1991 e n.1 547/1992, Mensagem n. 011/96 do Executivo feirense encaminhada à Câmara de Vereadores, Atas da Câmara de Vereadores do ano de 1989; e a entrevista com um vereador de mandato no ano 1991. Os resultados revelam que o processo de criação do CME em Feira de Santana se iniciou com mobilização popular, encabeçada pelo movimento de professores da educação básica, enfatizando a necessidade de sistematização de espaços coletivos e democráticos na educação municipal, no final dos anos de 1980. Os textos oficiais elaborados no início da criação e organização do CME de Feira de Santana, Lei Municipais n. 037/90 n. 1.477/91 e 1.547/92 revelam tensões, debates, escuta do contraditório e culminam com a construção hibrida que ora revela a tendência de participação e democracia ora a tendência de centralizadora no âmbito da Educação. A descontinuidade administrativa, ocasionada pela forma de gerir e a priorização de outras ações dos novos gestores públicos, além da falta de mobilização docente para a continuidade dos debates acerca do CME e mudança de gestores em Feira de Santana foram aspectos que influenciaram a não continuidade das ações voltadas para a criação e implementação do CME em Feira de Santana até os anos de 1996.

2

Zoughbie, Daniel E., Tin Lok James Ng, Jacqueline Y. Thompson, Kathleen T. Watson, Rami Farraj e Eric L. Ding. "Ramadan fasting and weight change trajectories: Time-varying association of weight during and after Ramadan in low-income and refugee populations". PLOS Global Public Health 2, n. 10 (26 ottobre 2022): e0000371. http://dx.doi.org/10.1371/journal.pgph.0000371.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

Abstract (sommario):

Obesity is a significant driver of the global burden of non-communicable diseases. Fasting is one approach that has been shown to improve health outcomes. However, the effects of Ramadan fasting differ in that the type, frequency, quantity, and time of food consumption vary. This phenomenon requires in-depth evaluation considering that 90% of Muslims (~2 billion people) fast during Ramadan. To address this issue, we evaluated the pattern of weight change during and following Ramadan for a total of 52 weeks. The study was conducted in Amman, Jordan. Between 2012 and 2015, 913 participants were recruited as part of a trial investigating the efficacy of a weight loss intervention among those with or at risk for diabetes. Weight was measured weekly starting at the beginning of Ramadan, and changes were analyzed using discrete and spline models adjusted for age, sex, and trial group. Results show slight weight gain within the first two weeks and weight loss in the subsequent weeks. During the first week of Ramadan, the estimate for a weight reduction was 0·427 kg, (95% CI: -0·007, 0·861), increasing to 1·567 kg, (95% CI: 2·547, 3·527) at week 26. There was clear evidence of gradual weight gain from about 4 to 15 weeks and a drop towards the end of the investigation at week 28 (-0·12kg, 95% CI: -0·89, 0·56). Our results show that weight changes occurred during and after Ramadan. Weight fluctuations may affect health risks, and thus, findings from this study can inform interventions. Public health agencies could leverage this period of dietary change to sustain some of the benefits of fasting. The authors (DEZ, EFD) acknowledge the Mulago Foundation, the Horace W. Goldsmith Foundation, Robert Wood Johnson Foundation, and the World Diabetes Foundation. TRIAL REGISTRATION. Clinicaltrials.gov registry identifier: NCT01596244.

3

Joshi, Y. N., e M. Mazzoni. "3d-Shell excitation in photoabsorption of atomic selenium". Canadian Journal of Physics 66, n. 4 (1 aprile 1988): 326–29. http://dx.doi.org/10.1139/p88-051.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

Abstract (sommario):

The photoabsorption spectrum of the inner 3d-shell excitation of atomic selenium was observed in the 500–170 Å region using the flash-pyrolysis technique. The observations, aided by the Hartree–Fock ab initio calculations and least squares fitted parametric calculations, have lead to the classification of 15 lines in the 4p4–3d94s24p5 transition array and 26 lines in the 4p4–3d94s24p4np transitions. Two series ionization limits have been calculated as 517 500 cm−1 (64.15 eV) and 530 000 cm−1 (67.70 eV).

4

Boadi, Dinah, e M. A. Price. "The effects of pre- and early post-calving management on reproductive performance of beef cows". Canadian Journal of Animal Science 76, n. 3 (1 settembre 1996): 337–42. http://dx.doi.org/10.4141/cjas96-050.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

Abstract (sommario):

One hundred and thirty-four pregnant beef cows (liveweight = 544.3 kg ± 73 3 kg SD; condition score = 3.5 ± 0.3 SD), were randomly assigned in January to five management treatments (combinations of feed restriction and weaning time) to study the effects on calving and rebreeding performance. Twenty-seven were feed-restricted (54.7 MJ DE d−1) for the last 3 mo of pregnancy then realimented (3REST); their calves were weaned in October. Thirty were feed-restricted for the last 3 mo of pregnancy (54.7 MJ DE d−1) and the first 2 mo of lactation (99.6 MJ DE d−1), then their calves were weaned and turned out to graze in June (5REST). The remaining 77 cows (UNREST) were supplemented on range with 153.5 MJ DE d−1 from January until calving. Their calves were weaned in either August (one group of 26 calves directly into a feedlot, a second group of 26 onto unsupplemented range) or October (25 calves directly into a feedlot). All cows grazed together on the range from June onwards. After calving, the restricted (3REST and 5REST) cows were significantly lighter (464.4 and 469.5 kg vs. 506.9 kg) and thinner (condition scores 2.5 and 2.6 vs. 3.0) than the UNREST cows, but the percentage of cows calving calf mortality, assisted births calving dates, udder scores and mean birth weight of calves were not affected (P > 0.05) by pre-calving nutrition. Catch-up growth was evident in both the 3REST and 5REST cows once exposed to higher energy feeding. There were no significant effects (P > 0.05) of the management (nutrition and weaning) treatments on the following year s breeding and calving performance. It is concluded that the combinations of nutrition and weaning used in this study did not necessarily impair calving or rebreeding performance of beef cows, which calved in condition score 2.5 or above. Key words: Beef cows, feed restriction, reproduction, condition score, rebreeding, birthweight

5

CUTCLIFFE, J. A. "EFFECTS OF LIME AND GYPSUM ON YIELDS AND NUTRITION OF TWO CULTIVARS OF BRUSSELS SPROUTS". Canadian Journal of Soil Science 68, n. 3 (1 agosto 1988): 611–15. http://dx.doi.org/10.4141/cjss88-059.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

Abstract (sommario):

Field experiments were carried out at different locations in Prince Edward Island each year for 3 consecutive years to determine the effects of calcific limestone, dolomitic limestone, and gypsum on yields and nutrition of two cultivars of Brussels sprouts (Brassica oleracea var. gemmifera). The soils at the sites selected had initial pH levels of 4.9–5.7. Preplant, broadcast applications of gypsum at 5.5 t ha−1 resulted in yield increases of about 30% at all locations. Analysis of leaf tissue collected when the sprouts began to form indicated that Ca, Mg, Mn and Zn concentrations of approximately 1.4–2.6%, 0.25–0.32%, 88–274 μg g−1 and 26–35 μg g−1, respectively, are within the sufficiency range. The incidence of internal browning was not affected by either the lime or gypsum treatments at the two locations where this disorder occurred. Key words: Lime, gypsum, yield, leaf tissue nutrient concentration, internal browning, Brussels sprouts

6

Vladimirov, Vladimir, Antonina Mostyakova, Leonid Egorov e Filus Agiev. "POTATO PRODUCTIVITY DEPENDING ON THE METHOD OF APPLICATION OF GROWTH REGULATOR AND CALCULATED BACKGROUND OF MINERAL NUTRITION ON THE GRAY FOREST STEPPE SOIL OF MIDDLE VOLGA REGION". Vestnik of Kazan State Agrarian University 14, n. 4 (5 febbraio 2020): 21–26. http://dx.doi.org/10.12737/2073-0462-2020-21-26.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

Abstract (sommario):

The reaction of the early ripening potato of Vineta variety to different methods of using growth regulators against the calculated background of mineral nutrition on the gray forest-steppe soil of middle Volga was studied. The effectiveness of processing planting tubers and foliar treatment of plants during their vegetation has been established. The experiments were carried out on the control without the introduction of NPK and on a fertilized background, designed to obtain a tuber crop of 40 tons per hectare. The studies were conducted on gray forest medium loam granulometric composition soil of “Zemlyaki” farm in Nizhnekamsk district of the Republic of Tatarstan. Field experiments were carried out in 2019 by employees of Plant Growing and Horticulture Department of Kazan State Agrarian University. The humus content in the arable layer of soil according to Tyurin is 3.35%, pH is 5.7, easily hydrolyzable nitrogen is 112 mg/kg of soil, mobile phosphorus is 156 mg/kg, exchange potassium is 136 mg/kg of soil, molybdenum is 0.07, copper is 0.52, boron - 0.7, zinc - 4.82 mg/kg. The effectiveness of the integrated use of growth regulators (treatment of planting tubers and foliar application of the drug during the growing season) has been established. The yield increase to control against the background without applying basic fertilizers amounted to 4.82 tons per hectare, and against the background of their application - 4.80 tons per hectare.

7

Christian Louis, Kouakou Ehaulier Soh, Same Bebey Francine, Sougué Charles, Seri Serge Landry, Yao Konan Joe Clauvis, Traore Aissata, Koffi Joseph Kan Enock, Goua Jean Jacques, Goupille Phillipe e Daboiko Jean Claude Felix. "Apport de la Rééducation dans la Prise en Charge de la Lombalgie/Lomboradiculalgie Commune Chronique à Abidjan : Amélioration de la Douleur et de la Capacité Fonctionnelle dans 95% des Cas". European Scientific Journal, ESJ 19, n. 27 (30 settembre 2023): 97. http://dx.doi.org/10.19044/esj.2023.v19n27p97.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

Abstract (sommario):

Objectif : Evaluer l’apport de la rééducation dans la prise en charge de la lombalgie/lomboradiculalgie commune chronique (LRCC). Patients et méthodes : Il s’est agi d’une étude prospective transversale allant du 1er janvier 2015 au 1er mai 2016 (16 mois), portant sur des cas de LRCC vu en rééducation au CHU de Cocody à Abidjan en Côte d’ivoire. L’échelle Eifel a permis d’évaluer la capacité fonctionnelle des patients. Il s’agissait de comparer l’intensité de la douleur et de son retentissement fonctionnel avant et après rééducation. Résultats : Sur 1380 patients vus, 86 souffraient de LRCC (6,23 %) soit 46 cas de lombalgie isolée (53,5%) et 40 cas de lomboradiculalgie (46,5%). Leur âge moyen était de 49,9 ans +/- 11,7 (extrêmes : 14 et 71 ans) et le sex ratio de 0,43 (26 hommes et 60 femmes). Le nombre moyen de séances de rééducation effectué était de 13,5±5,2 (Extrêmes : 5 et 25) avec une durée moyenne de 1,6 mois ±0,7 (Extrêmes : 1 et 5). L’évolution clinique était favorable chez 82 patients (95,35%). L’échelle visuelle analogique (EVA) moyenne était de 6,3±2 avant la rééducation, et de 1,8±1,6 après rééducation. Le score moyen de l’échelle EIFEL était de 13,38±5,7 avant la rééducation et de 3,6±4,82 après rééducation. Il existait une amélioration statistiquement significative de l’intensité de la douleur (p=0,02), et de la capacité fonctionnelle des patients après la rééducation (p=0,03). Conclusion : Les patients souffrant de LRCC consultent dans un contexte hyperalgique et invalidant en rééducation au CHU de Cocody. Les séances de rééducation permettent une amélioration de la douleur et de la capacité fonctionnelle des patients. Objective: To evaluate the contribution of rehabilitation in the management of chronic low back pain/ lomboradiculalgia (LRCC). Patients and methods: This was a 16-month prospective cross-sectional study from January 1, 2015, to May 1, 2016, of LRCC cases seen in rehabilitation at the University Hospital of Cocody in Abidjan, Ivoiry Coast. The Eifel scale was used to assess the functional capacity of patients. The aim was to compare the intensity of pain and its functional impact before and after rehabilitation. Results: Of 1380 patients seen, 86 had LRCC (6.23%), i.e. 46 cases of isolated low back pain (53.5%) and 40 cases of lumbaradiculalgia (46.5%). Their mean age was 49.9 years +/- 11.7 (extremes: 14 and 71 years) and the sex ratio was 0.43 (26 men and 60 women). The average number of rehabilitation sessions performed was 13.5±5.2 (extremes: 5 and 25) with an average duration of 1.6 months ±0.7 (extremes: 1 and 5). The clinical evolution was favorable in 82 patients (95.35%). The mean visual analog scale (VAS) was 6.3±2 before rehabilitation, and 1.8±1.6 after rehabilitation. The mean EIFEL score was 13.38±5.7 before rehabilitation and 3.6±4.82 after rehabilitation. There was a statistically significant decrease in pain intensity (p=0.02), and a statistically significant improvement in patients' functional capacity after rehabilitation (p=0.03). Conclusion: Patients suffering from LRCC consult in a hyperalgesic and disabling context in rehabilitation at Cocody. The rehabilitation sessions allow an improvement of the pain and the functional capacity of the patients.

8

Brinkworth, Grant D., Thomas P. Wycherley, Pennie J. Taylor e Campbell H. Thompson. "A Health Care Professional Delivered Low Carbohydrate Diet Program Reduces Body Weight, Haemoglobin A1c, Diabetes Medication Use and Cardiovascular Risk Markers—A Single-Arm Intervention Analysis". Nutrients 14, n. 20 (20 ottobre 2022): 4406. http://dx.doi.org/10.3390/nu14204406.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

Abstract (sommario):

This study examined the effectiveness of a health care professional delivered low-carbohydrate diet program (Diversa Health Program) aiming to improve obesity/type-2-diabetes management for people living in Australia. 511 adults (Age:57.1 ± 13.7 [SD] yrs) who participated between January 2017–August 2021 for ≥30 days with pre-post data collected for ≥1 key outcome variable (body weight and HbA1c) were included in the analysis. Average participation duration was 218 ± 207 days with 5.4 ± 3.9 reported consultation visits. Body weight reduced from 92.3 ± 23.0 to 86.3 ± 21.1 kg (n = 506, p < 0.001). Weight loss was −0.9 ± 2.8 kg (−1.3%), −4.5 ± 4.3 kg (−5.7%) and −7.9 ± 7.2 kg (7.5%), respectively, for those with a classification of normal weight (n = 67), overweight (n = 122) and obese (n = 307) at commencement. HbA1c reduced from 6.0 ± 1.2 to 5.6 ± 0.7% (n = 212, p < 0.001). For members with a commencing HbA1c of <5.7% (n = 110), 5.7–6.4% (n = 55), and ≥6.5% (n = 48), HbA1c reduced −0.1 ± 0.2%, −0.3 ± 0.3%, and −1.4 ± 1.3%, respectively. For members with a commencing HbA1c ≥6.5%, 90% experienced a HbA1c reduction and 54% achieved a final HbA1c < 6.5. With inclusion and exclusion of metformin, respectively, 124 and 82 diabetes medications were prescribed to 63 and 42 members that reduced to 82 and 35 medications prescribed to 51 and 26 members at final visit. A health care professional delivered low-carbohydrate diet program can facilitate weight loss and improve glycaemic control with greatest improvements and clinical relevance in individuals with worse baseline parameters.

9

Laseter, Isaac H., Steven L. Finkelstein, Micaela J. Bagley, Dustin M. Davis, Karl Gebhardt, Caryl Gronwall, Robin Ciardullo, Gregory R. Zeimann, Erin Mentuch Cooper e Daniel Farrow. "A Search for Lensed Lyα Emitters within the Early HETDEX Data Set". Astrophysical Journal 940, n. 1 (1 novembre 2022): 9. http://dx.doi.org/10.3847/1538-4357/ac9186.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

Abstract (sommario):

Abstract The Hobby–Eberly Telescope Dark Energy Experiment (HETDEX) is a large-volume spectroscopic survey without preselection of sources, searching ∼540 deg2 for Lyα emitting galaxies (LAEs) at 1.9 < z < 3.5. Taking advantage of such a wide-volume survey, we perform a pilot study using early HETDEX data to search for lensed Lyα emitters (LAEs). After performing a proof of concept using a previously known lensed LAE covered by HETDEX, we perform a search for previously unknown lensed LAEs in the HETDEX spectroscopic sample. We present a catalog of 26 potential LAEs lensed by foreground, red, non-star-forming galaxies at z ∼ 0.4–0.7. We estimate the magnification for each candidate system, finding 12 candidates to be within the strong lensing regime (magnification μ > 2). Follow-up observations of these potential lensed LAEs have the potential to confirm their lensed nature and explore these distant galaxies in more detail.

10

Mukherjee, Akash, Denai R. Milton, Elias Jabbour, Marina Konopleva, Courtney Denton Dinardo, Alison Gulbis, Farhad Ravandi et al. "Allogeneic stem cell transplantation (AlloSCT) for patients (pts) with acute leukemia following venetoclax-based therapy." Journal of Clinical Oncology 37, n. 15_suppl (20 maggio 2019): 7047. http://dx.doi.org/10.1200/jco.2019.37.15_suppl.7047.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

Abstract (sommario):

7047 Background: BCL-2 inhibitor Ven has shown a promising benefit in pts with acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). There is paucity of information about the safety and efficacy of alloSCT post Ven. Methods: We conducted a retrospective analysis of 35 AML/ALL pts who received alloSCT following Ven-based therapies between 2013-2018 at MDA. Results: Median age at alloSCT was 60 years and 15 (43%) pts had an age-adjusted HCT-CI score ≥ 4. Disease diagnosis – AML (n = 31; 89%), ALL (n = 4; 11%). Disease status at transplant was CR1 (n = 17; 49%), CR2/CR3 (n = 9; 26%) or refractory (n = 9; 26%). 20/26 (77%) CR pts were MRD-negative. Median # of prior therapies was 2 (range 1-7) and 4 (11%) pts had failed a prior alloSCT. AML pts were classified by ELN 2017 criteria to have favorable, intermediate and adverse risks in 16%, 23% and 61% respectively. Ven was provided in combination of hypomethylating agents (HMA) or other chemotherapies in 26 (74%) and 9 (26%) pts, respectively. Among pts treated with Ven + HMA, some also received IDH1/2 inhibitors (n = 7, 20%), FLT3 inhibitors (n = 4; 11%) or anti-PD1 (n = 3, 9%). Median duration of Ven-based treatment was 2 months (range 0.5- 4.6). Ven was discontinued in 6 (17%) pts due to adverse events (n = 4) or progression (n = 2); the remaining pts (83%) continued their Ven-therapy as a bridge to alloSCT. The median time from last Ven dose and transplant was 26 days. Conditioning regimens were melphalan-based reduced intensity (n = 26, 74%), or busulfan-based myeloablative regimens (n = 9; 26%). Donor source was matched -unrelated (n = 14, 40%), -related (n = 9; 26%) or haplo- (n = 12; 34%). GVHD prophylaxis consisted of tacrolimus with either PT-Cy in 25 (71%) pts or methotrexate in 10 (29%) pts. All pts engrafted (median day 30 donor cells = 100%). Median days to ANC > 500 and platelets > 20K was 15.5 and 22.5, respectively. With a median follow up of 5.7 months (range 0.7-15.4), the 1-year rates of OS, PFS, and NRM were 71%, 63% and 3% respectively. CI of acute grade 2-4 and 3-4 GVHD were 26% and 3% respectively. Four pts died: 3 because of disease relapse and 1 of infection. Conclusions: AlloSCT is a safe and feasible consolidation treatment option in acute leukemia pts who were pre- treated with Ven, without excessive risk of NRM or acute GVHD. Larger prospective studies are required to validate our observations.

11

Polupanov, A. G., T. B. Zalova, F. T. Rysmatova, M. T. Duishenalieva, T. A. Romanova e A. S. Dzhumagulova. "Relationship of tumor necrosis factor-alpha and interleukin-10 with the development of fatal and non-fatal complications in patients with essential hypertension during mid-term follow-up". "Arterial’naya Gipertenziya" ("Arterial Hypertension") 25, n. 5 (31 gennaio 2020): 540–48. http://dx.doi.org/10.18705/1607-419x-2019-25-5-540-548.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

Abstract (sommario):

Objective. To study the association of tumor necrosis factor alpha (TNF-α) and interleukin-10 (IL-10) with the development of fatal and non-fatal complications in patients with essential hypertension (EHTN) in the process of mid-term follow-up.Design and methods. 90 patients with EHTN aged 40 to 75 years (average age 56,4 ± 8,1 years) were observed, including 47 women and 43 men. The follow-up period ranged from 20 to 26 months (median observation — 24 months). At baseline, we assessed height, weight, body mass index, waist circumference, blood pressure and heart rate, fasting glucose, serum creatinine with the estimated glomerular filtration rate by CKD-EPI, lipid profile, serum levels of TNF-α and IL-10 by enzyme-linked immunosorbent tests (“CITOKIN — STIMUL — BEST”, Novosibirsk, Russia).Results. A cumulative decrease in the proportion of patients with EHTN without development of fatal and non-fatal cardiovascular complications at follow-up was 70,73 %. When analyzing the associations between cytokines and the development of fatal and non-fatal complications in EHTN patients at term follow-up, we found no difference in TNF-α levels in EHTN patients who reached the end-point and patients without complications (8,31 ± 0,97 vs 8,37 ± 1,33 pg/ml, respectively, p > 0,05), while IL-10 level was higher in patients without complications compared to n patients with complicated EHTN (15,9 ± 3,3 vs 13,5 ± 2,3 pg/ml, respectively, p < 0,01). Logistic regression analysis showed that only systolic blood pressure was an independent risk factor associated with the development of EHTN complications during mid-term follow-up: hazard ratio (HR) — 1,03; 95 % confidence interval (CI) 1,00-1,05. In addition, an increase in IL-10 level was an independent anti-risk factor associated with a significant 25 % reduction in the risk of EHTN complications (HR 0,75; 95 % CI 0,57-0,99).Conclusions. An increased IL-10 concentration was an independent anti-risk factor for the complicated EHTN during mid-term follow-up associated with a 25 % reduction in the risk of fatal and non-fatal complications. At the same time, we did not find the association of the TNF-α level with prognosis in EHTN patients during mid-term follow-up.

12

Brandenburg, R. L., e P. T. Hertl. "Alfalfa Weevil Control on Alfalfa, North Carolina, 1990". Insecticide and Acaricide Tests 16, n. 1 (1 gennaio 1991): 126–27. http://dx.doi.org/10.1093/iat/16.1.126a.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

Abstract (sommario):

Abstract A 6-yr-old stand of Cimmaron alfalfa located 15 miles south of Raleigh was used as a test site. Soil type was a sandy loam with 0.7% humic matter and a pH of 5.7. Plots were 20 × 20 and arranged in a randomized complete block with 4 replicates for each treatment. Treatments were applied on 6 Mar using a CO2-pressurized backpack sprayer using 8002 nozzles mounted on a hand-held boom delivering 30 gal/acre at 40 psi. Conditions at time of application were sunny and 70°F. Pretreatment counts were taken on 6 Mar and averaged 6.67 larvae/stem. Treatments were evaluated on 9, 12, 16, 23, 26 Mar; 1, and 5 Apr by taking 30 stems/plot and processing them through modified Tulgren funnels. Yield and quality samples were taken on 6 Apr after cutting alfalfa on 5 Apr. Quality samples were conducted by the state forage laboratory. All data were transformed X + 0.5 prior to analysis. Actual means are presented in the table. Dry matter sample results are presented as percentages.

13

Rutschman, D. H., W. Olivera e J. I. Sznajder. "Active transport and passive liquid movement in isolated perfused rat lungs". Journal of Applied Physiology 75, n. 4 (1 ottobre 1993): 1574–80. http://dx.doi.org/10.1152/jappl.1993.75.4.1574.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

Abstract (sommario):

The isolated perfused liquid-filled rat lung in a "pleural bath" was the model used to study liquid exchange across the lung epithelium. Active transport and passive solute movement between the air space, the vascular perfusate, and the bath result in concentration changes of the three markers (Evans blue-tagged albumin, 22Na+, and [3H]mannitol) instilled in the air space. A mathematical model was developed to estimate the active and passive solute transports and to interpret the results. Rat lungs were perfused at left atrial and pulmonary arterial pressures of 0 and 8 mmHg, respectively. Six rat lung experiments were conducted at 37 degrees C and six at 4 degrees C. The normothermic experiments demonstrate that active transport accounts for 26% of the Na+ movement out of the air space (17.3 +/- 0.7 nm/s) and that passive mechanisms account for the remaining 74% (48.0 +/- 5.7 nm/s). Hypothermia inhibits lung liquid clearance but does not affect passive solute movement, suggesting that lung liquid clearance is effected by active Na+ transport mechanisms.

14

Amin, A., V. DePril, O. Hamid, J. Wolchock, M. Maio, B. Neyns, K. Chin, R. Ibrahim, A. Hoos e S. O'Day. "Evaluation of the effect of systemic corticosteroids for the treatment of immune-related adverse events (irAEs) on the development or maintenance of ipilimumab clinical activity". Journal of Clinical Oncology 27, n. 15_suppl (20 maggio 2009): 9037. http://dx.doi.org/10.1200/jco.2009.27.15_suppl.9037.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

Abstract (sommario):

9037 Background: Ipilimumab, a fully human monoclonal antibody that inhibits cytotoxic T-lymphocyte antigen-4, has clinical activity at 10 mg/kg in patients (pts) with advanced melanoma. Most grade 3/4 immune-related adverse events (irAEs) associated with ipilimumab can be managed with systemic corticosteroids following established treatment guidelines. However, little has been reported about the effects of corticosteroids used to treat irAEs on ipilimumab antitumor responses. Methods: Across 3 phase II studies with 10 mg/kg ipilimumab monotherapy in advanced melanoma (CA184008, 022, and 007; N=283), 83 pts (29.3%) achieved disease control [complete/partial responses (CR/PR), or stable disease (SD) ≥12 weeks] and 43/83 (52%) received steroids for treatment of irAEs. The pts' ability to develop and maintain disease control in the presence and absence of steroids was analyzed. Disease control was assessed by modified World Health Organization (mWHO) criteria and novel immune-related response criteria (irRC) (Hodi FS, et al. J Clin Oncol 26: 2008 [May 20 suppl; abstr 3008]). The range of follow-up was 5.7–6.3 months. Results: Of 117 pts who received steroids prior to response assessment, 26 pts achieved CR or PR, or maintained SD without disease progression by mWHO, and the remaining 91 pts had PD. Of 166 pts who either never received steroids or received them after response assessment, 31 achieved a CR, PR, or SD (by mWHO). Further, of 26 pts with CR/PR by mWHO, 14 received subsequent steroids and 11 maintained a response, while of 12 pts who received no subsequent steroids, 9 maintained a response. Similar results were obtained if irRC were used (see table ). Conclusions: Systemic corticosteroids for treatment of irAEs do not appear to impact the development or maintenance of ipilimumab clinical activity in advanced melanoma. [Table: see text] [Table: see text]

15

Abdullah, Hend H. A. M., Nadia Amanzougaghene, Handi Dahmana, Meriem Louni, Didier Raoult e Oleg Mediannikov. "Multiple vector-borne pathogens of domestic animals in Egypt". PLOS Neglected Tropical Diseases 15, n. 9 (29 settembre 2021): e0009767. http://dx.doi.org/10.1371/journal.pntd.0009767.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

Abstract (sommario):

Vector Borne Diseases (VBDs) are considered emerging and re-emerging diseases that represent a global burden. The aim of this study was to explore and characterize vector-borne pathogens in different domestic animal hosts in Egypt. A total of 557 blood samples were collected from different animals using a convenience sampling strategy (203 dogs, 149 camels, 88 cattle, 26 buffaloes, 58 sheep and 33 goats). All samples were tested for multiple pathogens using quantitative PCR and standard PCR coupled with sequencing. We identified Theileria annulata and Babesia bigemina in cattle (15.9 and 1.1%, respectively), T. ovis in sheep and buffaloes (8.6 and 7.7%, respectively) and Ba. canis in dogs (0.5%) as well as Anaplasma marginale in cattle, sheep and camels (20.4, 3.4 and 0.7%, respectively) and Coxiella burnetii in sheep and goats (1.7 and 3%; respectively). New genotypes of An. centrale, An. ovis, An. platys-like and Borrelia theileri were found in cattle (1.1,3.4, 3.4 and 3.4%, respectively), An. platys-like in buffaloes (7.7%), An. marginale, An. ovis, An. platys-like and Bo. theileri in sheep (3.4, 1.7, 1.7 and 3.4%, respectively), An. platys, An. platys-like and Setaria digitata in camels (0.7, 5.4 and 0.7%, respectively) and Rickettsia africae-like, An. platys, Dirofilaria repens and Acanthocheilonema reconditum in dogs (1.5, 3.4, 1 and 0.5%, respectively). Co-infections were found in cattle, sheep and dogs (5.7, 1.7, 0.5%, respectively). For the first time, we have demonstrated the presence of several vector-borne zoonoses in the blood of domestic animals in Egypt. Dogs and ruminants seem to play a significant role in the epidemiological cycle of VBDs.

16

Douglass, Caitlin H., Cassandra J. C. Wright, Angela C. Davis e Megan S. C. Lim. "Correlates of in-person and technology-facilitated sexual harassment from an online survey among young Australians". Sexual Health 15, n. 4 (2018): 361. http://dx.doi.org/10.1071/sh17208.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

Abstract (sommario):

Background Technology-facilitated sexual harassment is an emerging phenomenon. This study investigates correlates of sexual harassment among young Australians. Methods: Participants aged 15-29 were recruited for an online survey. Participants reported how often in the past year they experienced sexual harassment in person, via phone, social media and dating apps. Correlates of in-person and technology-facilitated sexual harassment were identified using logistic regression. Results: Of all participants (n = 1272, 70% female), two-thirds reported sexual harassment in person, 34% through social media and 26% via phone. Of participants who used a dating app in the past year (n = 535), 57% experienced sexual harassment. Sexual harassment in person was correlated with being female (aOR = 9.2, CI = 6.9–12.2), trans and gender diverse (aOR = 2.6, CI = 1.2–5.7) and being aged 20–24 years (aOR = 1.5, CI = 1.1–2.1). Heterosexual identity reduced the odds of sexual harassment in person (aOR = 0.7, CI = 0.5–0.9). Technology-facilitated sexual harassment was correlated with female (aOR = 3.5, CI = 2.6–4.6) and trans and gender diverse identities (aOR = 3.0, CI = 1.4–6.5). Older age [25–29 years (aOR = 0.5, CI = 0.4–0.8)] and heterosexual identity (aOR = 0.7, CI = 0.5–0.9) significantly reduced the odds of technology-facilitated sexual harassment. Conclusion: Young people identifying as female, trans and gender diverse and non-heterosexual are at risk of in-person and technology-facilitated sexual harassment. Service and technology providers, academics, and policy makers must respond with innovative strategies.

17

Schindler, Jan-Torge, Eduardo Bañados, Thomas Connor, Roberto Decarli, Xiaohui Fan, Emanuele Paolo Farina, Chiara Mazzucchelli et al. "The Pan-STARRS1 z > 5.6 Quasar Survey. III. The z ≈ 6 Quasar Luminosity Function". Astrophysical Journal 943, n. 1 (1 gennaio 2023): 67. http://dx.doi.org/10.3847/1538-4357/aca7ca.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

Abstract (sommario):

Abstract We present the z ≈ 6 type-1 quasar luminosity function (QLF), based on the Pan-STARRS1 (PS1) quasar survey. The PS1 sample includes 125 quasars at z ≈ 5.7–6.2, with −28 ≲ M 1450 ≲ −25. With the addition of 48 fainter quasars from the SHELLQs survey, we evaluate the z ≈ 6 QLF over −28 ≲ M 1450 ≲ −22. Adopting a double power law with an exponential evolution of the quasar density (Φ(z) ∝ 10 k(z−6); k = −0.7), we use a maximum likelihood method to model our data. We find a break magnitude of M * = − 26.38 − 0.60 + 0.79 mag , a faint-end slope of α = − 1.70 − 0.19 + 0.29 , and a steep bright-end slope of β = − 3.84 − 1.21 + 0.63 . Based on our new QLF model, we determine the quasar comoving spatial density at z ≈ 6 to be n ( M 1450 < − 26 ) = 1.16 − 0.12 + 0.13 cGpc − 3 . In comparison with the literature, we find the quasar density to evolve with a constant value of k ≈ −0.7, from z ≈ 7 to z ≈ 4. Additionally, we derive an ionizing emissivity of ϵ 912 ( z = 6 ) = 7.23 − 1.02 + 1.65 × 10 22 erg s − 1 Hz − 1 cMpc − 3 , based on the QLF measurement. Given standard assumptions, and the recent measurement of the mean free path by Becker et al. at z ≈ 6, we calculate an H i photoionizing rate of ΓH I(z = 6) ≈ 6 × 10−16 s−1, strongly disfavoring a dominant role of quasars in hydrogen reionization.

18

Komrokji, Rami S., Amy E. DeZern, Katrina Zell, Najla H. Al Ali, Christopher Estling, Cassie Zimmerman, Wesley Hand et al. "Validation of International Working Group (IWG) Response Criteria in Higher-Risk Myelodysplastic Syndromes (MDS): A Report on Behalf of the MDS Clinical Research Consortium (MDS CRC)". Blood 126, n. 23 (3 dicembre 2015): 909. http://dx.doi.org/10.1182/blood.v126.23.909.909.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

Abstract (sommario):

Introduction The primary goal for treatment of higher-risk MDS patients (pts) is to improve overall survival (OS) and delay acute myeloid leukemia (AML) evolution. The IWG 2006 response criteria are used in clinical trials and in clinical practice for assessing efficacy of MDS therapies. These criteria were originally proposed by an international group of experts based on available data and consensus. In an ad hoc landmark analysis of the AZA-001 study using the 2006 IWG criteria, pts who achieved hematological improvement (HI), complete response (CR), marrow CR (mCR), or partial response (PR) demonstrated improved OS. The aim of this study is to validate the IWG 2006 response criteria among a large cohort of higher-risk MDS pts. Methods Pts with higher-risk MDS (intermediate-2 (Int-2) or High Risk by International Prognostic Scoring System (IPSS)) who had received treatment and for whom details of response and outcome were available were included from the MDS CRC database. Pts were also classified per IPSS-R. The best response to treatment was categorized per the published IWG 2006 response criteria as CR, PR, mCR, HI, stable disease (SD) or progressive disease (PD). The primary endpoint was OS. Results We identified 646 treated higher-risk MDS pts. Table-1 summarizes baseline characteristics. The first line treatment was hypomethylating agent-based therapy (HMA) in 470 pts (74%). The median duration of follow up was 23.2 months (mo) (95% CI: (19.9, 26.5). Median OS from diagnosis was significantly longer for pts with int-2 IPSS risk disease IPSS (26.2 mo (21.5, 29.7)) compared to those who were High Risk (18.8 mo (15.9, 23.6); (p = 0.026). Median OS from diagnosis also differed by IPSS-R category (p < 0.001): for pts with Low risk (n = 6) it was not reached; Intermediate risk it was 41.7 mo (31.8, NR); High Risk it was 28.4 mo (24.1, 33.2); and for pts with Very High it was 16.5 mo (15.3, 19.1). The best IWG 2006 response rate for first line therapy among evaluable pts (n=597) was CR in 93 pts (16%), mCR in 10 (2%), PR in 57(10%), HI in 60 (10%), SD in 233 (39%), and PD in 144 (24%). The median OS based on IWG 2006 best response for first line therapy was 41 mo for CR, 12 mo for mCR, 26 mo for PR, 13 mo for HI, 14 mo for SD and 7 mo for PD. (p <0.001). CR was associated with better outcome compared to all other response groups. Pts with PR, HI, and SD had better outcome compared to PD, and similar outcome among the 3 groups. There was no difference in rate of AML transformation among response groups except in PD pts compared to others. For pts who were treated with HMA as first line therapy, the best response rates by IWG 2006 criteria were CR in 15%, mCR in 2%, PR in 10%, HI in 12%, SD in 40% and PD in 21%. Median OS in mo from time of HMA therapy based on response was: CR 19 (16.3, NR), mCR: 9 (7.1, NR), PR: 13 (8.8, NR), HI: 11 (7.7, 19.0), SD: 11.0 (8.5, 12.6), and PD: 3 (2.3, 3.9). (p <0.001) The best response by IWG 2006 criteria remained predictive of OS after adjusting for IPSS-R risk group. HR 0.30 (95% CI 0.2-0.4) for CR, and 0.57 (95% CI 0.45-0.7) for mCR/PR/HI compared to PD, (p <0.001) Conclusions: The best response by IWG 2006 criteria to first line therapy in higher-risk MDS correlates with OS. Pts who achieved CR had the best OS, while pts who achieved SD or better response had improved outcome compared to PD, with mCR having an OS equivalent to SD. The CR by IWG 2006 response criteria can be used as a surrogate endpoint for OS in higher-risk MDS pts in randomized Phase II studies determining comparison arms of Phase III trials, and for regulatory purposes. Table 1. Baseline characteristics Variable Total n=646 Age Median 68 Gender Male 399/645(62%) Race White 566/633 (89%) t-MDS Yes 161/545/514 (30%) WHO RA RARS RCMD RAEB-I RAEB-II MDS-U MDS/MPN CMML 5/527 (1%) 7/527 (1%) 69/527 (13%) 1153/527 (29%) 284/527 (54%) 3/527 (1%) 5/527 (1%) 1/527 (1%) IPSS Intermediate-II High 468/646 (72%) 178/646 (28%) R-IPSS Very low Low Intermediate High Very High 0 6/621 (1%) 74/621 (12%) 211/621 (34%) 330/621 (53%) IPSS karyotype Good Intermediate Poor 135/642 (21%) 118/642 (18%) 389 /642 (61%) IPSS-R karyotype Very good Good Intermediate Poor Very poor 7/642 (1%) 137/642 (21%) 134/642 (21%) 118/642 (18%) 246/642 (38%) Allogeneic transplant Yes 158/554 (29%) First line therapy HMA Chemotherapy IMiDClinical trial other 470/634 (74%) 57/634 (9%) 43/634 (7%) 25/634 (4%) 38/634 (6%) Lab (mean) Hgb (n=514) Platelets (n=514) ANC (n=514) Bone marrow blasts (n=639) 9.2 94 1.6 10% Disclosures Komrokji: Novartis: Research Funding, Speakers Bureau; Incyte: Consultancy; Pharmacylics: Speakers Bureau; Celgene: Consultancy, Research Funding. Steensma:Incyte: Consultancy; Amgen: Consultancy; Celgene: Consultancy; Onconova: Consultancy. Sekeres:TetraLogic: Membership on an entity's Board of Directors or advisory committees; Celgene Corporation: Membership on an entity's Board of Directors or advisory committees; Amgen: Membership on an entity's Board of Directors or advisory committees.

19

Zhang, Peiyang, Baicheng Wang, Xiaowei Zhang, Ziqi Song, Wenjun Bai, Qing Li e Tao Xu. "Suprapubic Liposuction With a Modified Devine’s Technique for Buried Penis Release in Adults". Plastic Surgery 28, n. 3 (20 aprile 2020): 172–78. http://dx.doi.org/10.1177/2292550320903440.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

Abstract (sommario):

Background: With the increasing prevalence of overweight and obesity, adult-acquired buried penis is more common in recent years. Many surgical techniques have been reported. However, none is the gold standard. Objective: To evaluate the safety and efficacy of combining suprapubic liposuction and modified Devine’s technique for penile lengthening in adult patients with buried penis due to obesity Methods: From September 2015 to June 2018, 26 consecutive suitable patients (mean age: 33 ± 5.7 years, mean body mass index: 29 ± 5.4 kg/m2) with a buried penis received suprapubic liposuction and modified Devine’s technique for penis release in our medical centre. A retrospective study was conducted. Their penile length from tip to the skin (flaccid) was measured pre- and post-operatively. The amount of liposuction was also recorded accordingly. Results: The mean length of the follow-up on the 26 patients is 18 ± 7.1 months (range 3-33 months). The average amount of liposuction is 450 ± 90.2 mL. The average penile length measured preoperatively, post-operatively (on table), and 3 months after the operation is 2.9 ± 1.3, 7.4 ± 2.1, and 5.3 ± 1.8 cm, respectively. The post-operative penile length had significantly increased by 4.5 ± 1.6 cm (on table) and 2.4 ± 0.7 cm (3 months post-operation) with a P value <.05. No patient had difficulties in sexual intercourse or urination post-operatively. None of the patients were dissatisfied with their surgical outcomes. Conclusions: The combination of suprapubic liposuction and modified Devine’s technique is a safe and effective method for releasing the buried penis of adults with satisfying outcomes.

20

Andrioli, Kleber Gustavo, e Paulo Cesar Sentelhas. "Brazilian maize genotypes sensitivity to water deficit estimated through a simple crop yield model". Pesquisa Agropecuária Brasileira 44, n. 7 (luglio 2009): 653–60. http://dx.doi.org/10.1590/s0100-204x2009000700001.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

Abstract (sommario):

The objective of this work was to determine the sensitivity of maize (Zea mays) genotypes to water deficit, using a simple agrometeorological crop yield model. Crop actual yield and agronomic data of 26 genotypes were obtained from the Maize National Assays carried out in ten locations, in four Brazilian states, from 1998 to 2006. Weather information for each experimental location and period were obtained from the closest weather station. Water deficit sensitivity index (Ky) was determined using the crop yield depletion model. Genotypes can be divided into two groups according to their resistance to water deficit. Normal resistance genotypes had Ky ranging from 0.4 to 0.5 in vegetative period, 1.4 to 1.5 in flowering, 0.3 to 0.6 in fruiting, and 0.1 to 0.3 in maturing period, whereas the higher resistance genotypes had lower values, respectively 0.2-0.4, 0.7-1.2, 0.2-0.4, and 0.1-0.2. The general Ky for the total growing season was 2.15 for sensitive genotypes and 1.56 for the resistant ones. Model performance was acceptable to evaluate crop actual yield, whose average errors estimated for each genotype ranged from -5.7% to +5.8%, and whose general mean absolute error was 960 kg ha-1 (10%).

21

Wenk, Manuel, Christina Massoth, Daniel M. Pöpping e Michael Möllmann. "Feasibility of Cervical Epidural Anesthesia for Breast Cancer Surgery". Anesthesiology Research and Practice 2017 (2017): 1–5. http://dx.doi.org/10.1155/2017/7024924.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

Abstract (sommario):

Background. Effects of perioperative cervical level neuraxial blocks on the dissemination of cancer metastases have become a matter of substantial interest. However, experience with these catheters has been limited and data on feasibility and efficacy is sparse. Methods. Data from 39 patients scheduled to undergo breast cancer surgery while awake with a cervical epidural alone was retrospectively analyzed. Results. In 26 patients (66,7%, 95% CI 51,7–81,7) the cervical epidural catheter was sufficient for surgery. In one patient (2.6%, 95% CI 0–7.6) identification of the epidural space was not possible. Four patients (10.3%, 95% CI 0,7–19,9) had an insufficient sensory block. Seven patients (17.9%, 95% CI 5,7–30,1) had a partially insufficient sensory block. Rates of failed epidural blocks were not significantly different between different insertion levels. 21 patients (80.8%, 95% CI 65,4–96,1) developed hypotension and required an intravenous vasopressor. One patient developed nausea. In one patient the dura was accidentally punctured. No neurological damage was observed. No other major complications were observed. Discussion. Epidural punctures in the cervical region are feasible but do bear potential for major complications. Anesthesiologists should familiarize themselves with high epidural block techniques.

22

Kolosov, Alexey V., S. I. Achkasov, E. S. Surovegin, R. Yu Khryukin, A. A. Likutov e O. I. Sushkov. "Efficacy and safety of hybrid laparo-endoscopic surgery for colon tumors (systematic review and meta-analysis)". Koloproktologia 22, n. 4 (21 dicembre 2023): 135–46. http://dx.doi.org/10.33878/2073-7556-2023-22-4-135-146.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

Abstract (sommario):

Aim: to compare the efficacy and safety of hybrid laparo-endoscopic operations and laparoscopic segmental colectomy for benign endoscopically non-removable colorectal tumors.Materials and Methods: systematic review and meta-analysis included 17 studies which evaluate the results of hybrid laparo-endoscopic procedure (main group) and laparoscopic segmental colectomy (control group). The study included 835 patients — 517 in main group and 318 controls.Results: operation time was significantly lower in main than in control group (mean difference = −38,7 minutes; 95% CI: −51,4 — −26, p < 0,00001). There was significant difference in postoperative hospital stay. It was shorter in main group (mean difference = −2,3 days; 95% CI: −3,17 — −1,57, p < 0,00001). There was not significant difference between odds ratio of postoperative morbidity (OR = 0,7; 95% CI: 0,38–1,53, p = 0,44), mortality (OR = 0,4; 95% CI: 0,07–3,11, p = 0,43) and local recurrence rate as well (OR = 2,8; 95% CI: 0,68–11,35, p = 0,15).Conclusion: the hybrid laparo-endoscopic technique patients with benign endoscopically non-removable colon tumors does not increase the postoperative morbidity and mortality. At the same time, the hybrid technology reduces the operation time and postoperative hospital stay.

23

Powles, Thomas, Ajjai Shivaram Alva, Mustafa Ozguroglu, Peter H. O'Donnell, Yohann Loriot, Tibor Csoszi, Jacqueline Vuky et al. "Post hoc pooled analysis of first-line (1L) pembrolizumab (pembro) for advanced urothelial carcinoma (UC): Outcomes by response at week nine in KEYNOTE-052 and KEYNOTE-361." Journal of Clinical Oncology 40, n. 6_suppl (20 febbraio 2022): 519. http://dx.doi.org/10.1200/jco.2022.40.6_suppl.519.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

Abstract (sommario):

519 Background: Pembro is a 1L treatment for cisplatin-ineligible pts with UC. This post hoc landmark analysis evaluated clinical outcomes by response at 9 wk to 1L pembro monotherapy in pts with advanced/unresectable or metastatic UC from the single-arm phase 2 KEYNOTE-052 (NCT02335424) and the randomized phase 3 KEYNOTE-361 (NCT02853305) trials. Methods: Cisplatin-ineligible pts with advanced UC were enrolled in KEYNOTE-052 and received pembro (200 mg Q3W for ≤2 y). Platinum-eligible pts with advanced UC who had not previously received systemic chemotherapy (chemo) were enrolled in KEYNOTE-361 and randomly assigned 1:1:1 to receive pembro (200 mg Q3W for ≤2 y), pembro + chemo (1000 mg/m2 gemcitabine on d1 and d8 + cisplatin [70 mg/m2] or carboplatin [AUC 5] on d1 of each 3-wk cycle), or chemo. The primary analysis group included pembro monotherapy–treated pts; the sensitivity analysis group included pembro monotherapy–treated pts from KEYNOTE-052 and the choice of carboplatin subpopulation of pembro monotherapy–treated pts from KEYNOTE-361. Landmark analyses of OS by pts with CR, PR, SD, or PD per RECIST v1.1 by BICR at first imaging assessment (wk 9) were pooled for the ITT populations. Duration of CR/PR/SD and OS were estimated using the Kaplan-Meier method. Data cutoffs were Sep 26, 2020 (KEYNOTE-052) and Apr 29, 2020 (KEYNOTE-361). Results: The primary analysis group included 681 pembro-treated pts (KEYNOTE-052, N = 374; KEYNOTE-361, N = 307); the sensitivity analysis group included 544 pembro-treated pts (KEYNOTE-052, N = 374; KEYNOTE-361, N = 170). Median time from randomization to cutoff was 51.9 mo (range, 22.0-65.3) and 53.7 mo (range, 22.0-65.3) for the primary and sensitivity analysis groups, respectively. Twenty-five pts (4.6%) had CR and 135 (24.6%) had PR (primary group); 17 pts (3.9%) had CR and 105 (24.1%) had PR (sensitivity group). Median DOR was 25.9 mo for pts with CR/PR at wk 9; pts with CR/PR or SD at wk 9 had longer OS than pts with PD at wk 9 (Table). Conclusions: In this post hoc analysis, pts with advanced UC in KEYNOTE-052 and KEYNOTE-361 with CR/PR at wk 9 had better clinical outcomes with pembro monotherapy than pts with SD or PD; 1L pembro monotherapy continues to show efficacy in advanced UC. Clinical trial information: NCT02335424 and NCT02853305. [Table: see text]

24

Reichert, Dorothea, Nikolaus Scheper, Dirk Müller-Wieland, Dennis Häckl, Andreas Bayer, Michael Horst e Baptist Gallwitz. "Ambulante Diabetesversorgung in Deutschland – Ergebnisse einer Strukturerhebung in diabetologischen Praxen und Einrichtungen". Diabetologie und Stoffwechsel 13, n. 02 (aprile 2018): 167–73. http://dx.doi.org/10.1055/a-0578-8296.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

Abstract (sommario):

Zusammenfassung Hintergrund Die Zahl der Erkrankungen an Diabetes mellitus nimmt in Deutschland zu. Um den Status quo der ambulanten spezialisierten Diabetesversorgung bundesweit zu untersuchen, wurde eine Umfrage in diabetologischen Praxen und Einrichtungen bezüglich ihrer Strukturen, der Organisation und der Qualifikation der ärztlichen sowie nichtärztlichen Mitarbeiter durchgeführt. Methode Ärzte des Bundesverbandes Niedergelassener Diabetologen (BVND) und der Deutschen Diabetes Gesellschaft (DDG) erhielten einen Fragebogen. Der Befragungszeitraum umfasste 3 Monate. Die Auswertung der Fragebögen erfolgte zentral. Ergebnisse Insgesamt 2642 Ärzte wurden kontaktiert. Die Rücklaufquote betrug 53,2 % (1405 Ärzte in 540 Praxen). 51 % der Praxen waren Gemeinschaftspraxen. 67 % der Praxen betrieben fächerübergreifende Kooperationen (47 % mit Hausärzten, 37 % mit Internisten). 79 % der Praxen übernahmen zusätzlich hausärztliche Funktionen und betrieben fachübergreifende Qualitätszirkel. 96 % der Befragungsteilnehmer nahmen am DMP Diabetes teil. 41 % der Patienten wurden gezielt diabetologisch überwiesen. Der Einsatz von evaluierten Schulungsprogrammen betrug bis zu 82 %. 65 % der Einrichtungen boten Programme für Migranten an. 51 % der Einrichtungen hatten eine Zulassung als Fußzentrum durch die KV. Das mittlere Alter der Ärzte betrug 53 Jahre, nur 7 % waren jünger als 40. Der Anteil an diabetologischem nichtärztlichem Fachpersonal betrug 26 – 42 % des Gesamtpersonals. Schlussfolgerungen Die Einrichtungen arbeiten qualitätsgesichert mit fachspezifischem Personalschlüssel. Die Schwerpunktprofile der Einrichtungen sind heterogen. Anhand der Altersstruktur und der Diabetesentwicklung zeichnet sich ein möglicher Versorgungsengpass ab.

25

Bailey, Stephen J., Jonathan Fulford, Anni Vanhatalo, Paul G. Winyard, Jamie R. Blackwell, Fred J. DiMenna, Daryl P. Wilkerson, Nigel Benjamin e Andrew M. Jones. "Dietary nitrate supplementation enhances muscle contractile efficiency during knee-extensor exercise in humans". Journal of Applied Physiology 109, n. 1 (luglio 2010): 135–48. http://dx.doi.org/10.1152/japplphysiol.00046.2010.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

Abstract (sommario):

The purpose of this study was to elucidate the mechanistic bases for the reported reduction in the O2cost of exercise following short-term dietary nitrate (NO3−) supplementation. In a randomized, double-blind, crossover study, seven men (aged 19–38 yr) consumed 500 ml/day of either nitrate-rich beetroot juice (BR, 5.1 mmol of NO3−/day) or placebo (PL, with negligible nitrate content) for 6 consecutive days, and completed a series of low-intensity and high-intensity “step” exercise tests on the last 3 days for the determination of the muscle metabolic (using31P-MRS) and pulmonary oxygen uptake (V̇o2) responses to exercise. On days 4–6, BR resulted in a significant increase in plasma [nitrite] (mean ± SE, PL 231 ± 76 vs. BR 547 ± 55 nM; P < 0.05). During low-intensity exercise, BR attenuated the reduction in muscle phosphocreatine concentration ([PCr]; PL 8.1 ± 1.2 vs. BR 5.2 ± 0.8 mM; P < 0.05) and the increase in V̇o2(PL 484 ± 41 vs. BR 362 ± 30 ml/min; P < 0.05). During high-intensity exercise, BR reduced the amplitudes of the [PCr] (PL 3.9 ± 1.1 vs. BR 1.6 ± 0.7 mM; P < 0.05) and V̇o2(PL 209 ± 30 vs. BR 100 ± 26 ml/min; P < 0.05) slow components and improved time to exhaustion (PL 586 ± 80 vs. BR 734 ± 109 s; P < 0.01). The total ATP turnover rate was estimated to be less for both low-intensity (PL 296 ± 58 vs. BR 192 ± 38 μM/s; P < 0.05) and high-intensity (PL 607 ± 65 vs. BR 436 ± 43 μM/s; P < 0.05) exercise. Thus the reduced O2cost of exercise following dietary NO3−supplementation appears to be due to a reduced ATP cost of muscle force production. The reduced muscle metabolic perturbation with NO3−supplementation allowed high-intensity exercise to be tolerated for a greater period of time.

26

Barinov, Sergey Vladimirovich, Oksana Vyacheslavovna Lazareva, Boris Vasil’yevich Korneev, Lyudmila Leonidovna Shkabarnya, Mikhail Vladimirovich Grebenuk, Ekaterina Aleksandrovna Roshchupkina, Anna Vadimovna Belokopytova e Pavel Igorevich Sorokin. "To the matter about operational treatment of benign neoplasms of ovaries during pregnancy". Journal of obstetrics and women's diseases 64, n. 4 (15 settembre 2015): 13–20. http://dx.doi.org/10.17816/jowd64413-20.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

Abstract (sommario):

Purposes and tasks. To improve the result of treatment of benign ovarian tumor during pregnancy using information of a complex comparative analysis of surgical interventions performed by laparoscopy and laparotomy. Materials and methods. We examined 69 pregnant women who undergoing treatment of benign ovarian tumors by laparoscopic and laparotomic surgery. The analysis of clinical data, postoperative pain, postoperative complications and statistic assess were performed. Results. The average age of pregnant women in laparoscopy group was 26 ± 0,5 years and 29 ± 0,7 years in laparotomy group. The main indications for intervention were threatened miscarriage and ovarian torsion. All women received therapy for saving pregnancy in postoperative period. The laparoscopy was associated with a significant reduction in time compared to laparotomy (54,7 ± 2,6 and 64,5 ± 2,5 - appropriate, р = 0,003). The blood loss was 46,67 ± 29,9 ml in laparoscopy and 108,7 ± 58,6 ml in laparotomy group (р < 0,001). Postoperative pain was less in women who undergoing laparoscopic surgery. 29 (76.3 %) women had vaginal delivery in laparoscopy group, 22(70.9 %) - in laparotomy group. Conclusion. In pregnant women undergoing surgery for benign ovarian tumours, laparoscopy was associated with less operation time, postoperative pain, blood loss compared with laparotomic surgery. The optimal time for intervention is before 24 week of pregnancy.

27

Teplenky, M. P., E. V. Oleinikov e V. S. Bunov. "Hip reconstruction in patients with ischemic deformity of the proximal femur and associated acetabular dysplasia". Genij Ortopedii 26, n. 4 (dicembre 2020): 502–7. http://dx.doi.org/10.18019/1028-4427-2020-26-4-502-507.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

Abstract (sommario):

Introduction Acetabular dysplasia associated with ischemic deformity of the proximal femur leads to significant functional limitations and progressive hip osteoarthritis (OA). The best surgical approach, the timing and the volume of surgery are still controversial. Material and methods Outcomes of 32 patients with ischemic hip deformity were reviewed. The mean age at the time of surgery was 15.8 ± 0.7 (range, 12–24) years. The mean follow-up period was 4.2 ± 0.4 years. Clinical outcomes were measured using the Merle d'Aubigné-Postel, Tönnis, Severin scoring scales and the grading system developed at the National Ilizarov Medical Research Center for Trauma and Orthopedics (NIMRC TO). Extra-articular (n = 24) and intra-articular (n = 8) procedures were produced for hip reconstructions. Results The hip function score was 5.2 ± 0.1 after extra-articular interventions and 4.3 ± 0.14 after intra-articular procedures. Postoperatively, hip joints were+ graded as Severin IIa (n = 18), Severin IIb (n = 10) and Severin III (n = 4). No arthritic changes occurred in 25 hips. In the remaining cases, OA either progressed (n = 4) or improved (n = 3). Outcomes were rated as good with 2.6 ± 0.03 scores (n = 17), fair with 2 ± 0.1 scores (n = 13) and poor with 1.41 ± 0.05 scores (n = 2) measured on the NIMRC TO scale. Conclusion The technologies offered for the reconstruction of both articular components have been shown to be effective in treatment of patients with ischemic hip deformity and associated acetabular dysplasia.

28

Upadhyaya, Santhosh, Olivia Campagne, Giles W. Robinson, Arzu Onar-Thomas, Brent Orr, Catherine A. Billups, Ruth G. Tatevossian et al. "Phase II study of alisertib as a single agent in recurrent or progressive atypical teratoid rhabdoid tumors." Journal of Clinical Oncology 38, n. 15_suppl (20 maggio 2020): 10542. http://dx.doi.org/10.1200/jco.2020.38.15_suppl.10542.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

Abstract (sommario):

10542 Background: We conducted a Phase II study of alisertib, small-molecule inhibitor of Aurora A kinase, as single-agent treatment in patients < 22 y with recurrent or progressive atypical teratoid rhabdoid tumors (ATRT) (NCT02114229). Methods: Patients received alisertib once daily [80 mg/m2 (enteric-coated tablets) or 60 mg/m2 (liquid)] on Days 1–7 of a 21-day cycle for 2 y or until progressive disease (PD). Therapy was considered promising if ≥10 patients were without PD by MR imaging at 12 wk. Molecular groups were determined using Infinium Methylation EPIC BeadChips and the Heidelberg classifier. Alisertib plasma concentrations were measured in cycle 1, on Days 1 (single dose) and 7 (steady state) and analyzed using population-based modeling. Results: Data from 30 patients representing all 3 molecular groups [SHH (10/26), MYC (10/26), TYR (6/26), unknown (4/26)] was analyzed. One patient remains on therapy. The study did not meet the efficacy end point as only 8/29 patients were without PD after 12 wk, including 1 with partial response. Progression-free survival (PFS) was 31%±8.2% at 6 months and 15.8%±6.5% at 1 y. One- year overall survival (OS) was 42.1%±9.2%. One patient remained on treatment for > 12 months, and another for > 18 months. The median treatment duration was 44 days (range, 2–653 days). There was no difference in OS (p = 0.096) or PFS (p = 0.98) by molecular groups. Neutropenia was the most common adverse effect (77%). After single-dose alisertib, we observed higher mean maximum concentration (Cmax) 10.1±3.0 µM and faster time to Cmax (Tmax = 1.2±0.7 h) in the 22 patients who received liquid formulation than those who received tablets (Cmax = 5.7±2.4 µM, Tmax = 3.4±1.4 h). Drug exposure did not differ between the formulations (AUC0-∞ = 58.6±25 h·µM). Average apparent oral clearance was 2.32 L/h per m2, which was about half that reported in adults. Serial CSF samples were collected in 2 patients; the CSF/plasma AUC ratios were 1.2%-2.7%. Conclusions: Although the study did not meet the efficacy end point, alisertib was well tolerated as a single agent in children with recurrent ATRT. A third of the patients demonstrated disease stabilization for > 6 months. Treatment response beyond 1 y was seen in 2 patients Clinical trial information: NCT02114229.

29

Wei, Chiming, e John C. Burnett. "Inhibition by calcium antagonism of circulating and renal endothelin in experimental congestive heart failure". American Journal of Physiology-Heart and Circulatory Physiology 278, n. 1 (1 gennaio 2000): H263—H268. http://dx.doi.org/10.1152/ajpheart.2000.278.1.h263.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

Abstract (sommario):

Endothelin (ET) is a potent vasoconstrictor and sodium-regulating peptide whose tissue and plasma concentrations are increased in congestive heart failure (CHF). ET may mediate its vasoconstrictor and sodium-regulatory actions secondary to an increase in intracellular calcium. Calcium influx may augment ET synthesis. Although felodipine, a dihydropyridine calcium-channel antagonist, is effective in reducing vascular resistance in generalized vasoconstriction, its actions in CHF on circulating and local tissue ET remain undefined. The current studies were designed to determine the modulating actions of felodipine (oral, 40 mg/day for 7 days; n= 6) in an experimental canine model of CHF produced by chronic thoracic inferior vena caval constriction (TIVCC) compared with normal ( n = 7) and TIVCC-alone ( n = 7) dogs. We hypothesized that felodipine would decrease circulating and renal ET. Plasma ET was significantly increased in TIVCC compared with normal dogs (26 ± 0.5 vs. 12 ± 0.7 pg/ml, P < 0.05) and was markedly decreased by felodipine compared with TIVCC alone (14 ± 3 vs. 26 ± 0.5 pg/ml, P < 0.05). Renal ET immunohistochemical staining demonstrated the presence of ET in normal kidney, which was markedly increased in renal cortex and medulla in TIVCC dogs. Renal cortical and medullary ET staining densities were markedly decreased with felodipine compared with those with TIVCC alone. In the TIVCC + felodipine group, cardiovascular hemodynamics also was markedly improved compared with the TIVCC-alone group [systemic vascular resistance: 27 ± 2 vs. 44 ± 3 resistance units (RU), P < 0.05; pulmonary vascular resistance: 3.3 ± 0.1 vs. 5.7 ± 0.4 RU, P < 0.05; cardiac output: 2.9 ± 0.2 vs. 1.7 ± 0.1 l/min, P < 0.05]. This study demonstrates important modulating inhibitory actions of felodipine on renal and plasma ET in an experimental model of CHF.

30

Galanis, Evanthia, Kurt A. Jaeckle, Matthew J. Maurer, Joel M. Reid, Matthew M. Ames, James S. Hardwick, John F. Reilly et al. "Phase II Trial of Vorinostat in Recurrent Glioblastoma Multiforme: A North Central Cancer Treatment Group Study". Journal of Clinical Oncology 27, n. 12 (20 aprile 2009): 2052–58. http://dx.doi.org/10.1200/jco.2008.19.0694.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

Abstract (sommario):

PurposeVorinostat, a histone deacetylase inhibitor, represents a rational therapeutic target in glioblastoma multiforme (GBM).Patients and MethodsPatients with recurrent GBM who had received one or fewer chemotherapy regimens for progressive disease were eligible. Vorinostat was administered at a dose of 200 mg orally twice a day for 14 days, followed by a 7-day rest period.ResultsA total of 66 patients were treated. Grade 3 or worse nonhematologic toxicity occurred in 26% of patients and consisted mainly of fatigue (17%), dehydration (6%), and hypernatremia (5%); grade 3 or worse hematologic toxicity occurred in 26% of patients and consisted mainly of thrombocytopenia (22%). Pharmacokinetic analysis showed lower vorinostat maximum concentration and area under the curve (0 to 24 hours) values in patients treated with enzyme-inducing anticonvulsants, although this did not reach statistical significance. The trial met the prospectively defined primary efficacy end point, with nine of the first 52 patients being progression-free at 6 months. Median overall survival from study entry was 5.7 months (range, 0.7 to 28+ months). Immunohistochemical analysis performed in paired baseline and post-vorinostat treatment samples in a separate surgical subgroup of five patients with recurrent GBM showed post treatment increase in acetylation of histones H2B and H4 (four of five patients) and of histone H3 (three of five patients). Microarray RNA analysis in the same samples showed changes in genes regulated by vorinostat, such as upregulation of E-cadherin (P = .02).ConclusionVorinostat monotherapy is well tolerated in patients with recurrent GBM and has modest single-agent activity. Histone acetylation analysis and RNA expression profiling indicate that vorinostat in this dose and schedule affects target pathways in GBM. Additional testing of vorinostat in combination regimens is warranted.

31

Baines, A. D., R. Drangova e C. Hatcher. "Dopamine production by isolated glomeruli and tubules from rat kidneys". Canadian Journal of Physiology and Pharmacology 63, n. 2 (1 febbraio 1985): 155–58. http://dx.doi.org/10.1139/y85-027.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

Abstract (sommario):

To locate the sites of dopamine (D) production in rat renal cortex, we separated glomeruli and proximal tubules by sieving or centrifugation in Percoll after collagenase digestion. After centrifugation layer I contained 60–80% glomeruli and 20–40% tubule fragments, half of which did not stain with alkaline phosphatase, layer II contained 0–5% glomeruli, 10–25% tubule fragments other than proximal tubules, and 70–85% proximal tubule fragments. Layer IV contained 85–95% proximal tubules. Gluconeogenic rates were (micromoles per hour per gram wet weight) as follows: I, 4 ± 1; II, 7 ± 2; and IV, 16 ± 1. Norepinephrine (NE) content was (picomoles per gram wet weight) I, 310 ± 30; II, 540 ± 40; IV, 195 ± 60. D content was (picomoles per gram wet weight) I, 26 ± 6; II, 46 ± 13; IV, 33 ± 7. Surgical denervation 4–6 days previously reduced the norepinephrine content of layers I and II to 35 ± 10 (p < 0.001) and of IV to 60 ± 20 (p < 0.05) and the D content of layers I and II to 13 ± 6 and 6 ± 6 pmol/g, respectively (p < 0.01); D content of layer IV was unchanged. D production from 10−7 M 3,4-dihydroxyphenylalanine (DOPA) was (nanomoles per gram per minute) I, 0.2 ± 0.03; II, 0.7 ± 0.1; IV, 1.0 ± 0.04. DOPA consumption was (nanomoles per gram per minute) I, 0.6 ± 0.1; II, 1.4 ± 0.3; and IV, 1.8 ± 0.2. Denervation did not change D production or DOPA consumption. Glomeruli without arterioles or tubules, obtained by sieving, contained no D or NE and did not produce D from DOPA. We conclude that proximal tubules produced at least five times more D from DOPA than glomeruli and distal tubules. Renal nerves did not contribute significantly to D production. We found no evidence of specific D-containing nerves associated with rat glomeruli.

32

Wennström, Ulfstand, Urban Bergsten e Jan-Erik Nilsson. "Early seedling growth of Pinus sylvestris after sowing with a mixture of stand and orchard seed in dense spacings". Canadian Journal of Forest Research 31, n. 7 (1 luglio 2001): 1184–94. http://dx.doi.org/10.1139/x01-050.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

Abstract (sommario):

Effects on early seedling growth of seeding stand and orchard seed of Pinus sylvestris L. in different mixtures (100, 75, 50, 25, and 0% of orchard seed) at 4-cm target spacing were quantified in one nursery and one field experiment during a 2- and 5-year period, respectively. In the field experiment, 50% mixtures at 8- and 12-cm target spacing were also studied. Seedlings from orchard seeds (OS) had in general higher growth rate than seedlings from stand seed (SS). In the nursery experiment, OS were 25% taller, had 41% larger above-soil biomass, and 18% larger root biomass than SS after 2 years when sown separately. However, root/shoot ratio was 26% less and the slenderness value (height/diameter ratio) was 11% greater for OS in comparison with SS. Stand seed in high competition, compared with low competition (mixture 75% vs. mixture 0%), were 11% taller, had 15% greater slenderness value, and 25% less root biomass after 2 years. OS had 9% greater slender value in mixture 100% compared with the 25% mixture. In the field experiment, the tallest OS in each plot were 22% taller and the largest OS had 103% larger stem volume than the tallest or largest SS when sown separately after 5 years. After a height-selection thinning to one seedling per plot at year five, 79% of the seedlings in 50% mixtures would be OS. Seedlings sown in 12-cm spacing were 69% taller and had 527% larger stem volume than seedlings in 4-cm spacing after 5 years. The investigation supports that orchard and stand seed could be direct seeded in a mixture. Low dosages of the more expensive orchard seeds could be used to obtain growth advantages. Stand seeds should be added to increase the number of seedlings to the desired spacing.

33

Diker, Gürkan, Artur Struzik, Sadi Ön e Raif Zileli. "The Relationship between the Hamstring-to-Quadriceps Ratio and Jumping and Sprinting Abilities of Young Male Soccer Players". International Journal of Environmental Research and Public Health 19, n. 12 (18 giugno 2022): 7471. http://dx.doi.org/10.3390/ijerph19127471.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

Abstract (sommario):

The correct torque ratio between the knee joint extensor and flexor muscle groups can effectively prevent injuries to the anterior cruciate ligament and hamstring strain. However, it is unclear whether a high torque ratio of the knee joint flexor muscles to the extensor muscles is beneficial for sport performance. Therefore, the aim of the study was to investigate the relationship between the hamstring-to-quadriceps (H/Q) ratio and sprint times (10- and 30-m) and jump heights (CMJ—countermovement jump and SJ—squat jump) in soccer players. The study examined 26 young elite soccer players (age: 18.1 ± 0.7 years; body height: 1.77 ± 0.05 m; body mass: 72.7 ± 5.7 kg). Knee joint flexor and extensor peak torques were assessed using the Cybex dynamometer (at 60°/s, 120°/s and 180°/s). Additionally, each participant performed the CMJ, SJ, and 30 m sprint. A significant relationship was obtained between the H/Q ratio (60°/s) and 30 m sprint time (r = 0.47). The positive direction of this relationship may indicate an important role of knee joint extensors in sprinting performance. Moreover, the H/Q ratio was not significantly associated with the CMJ, SJ or 10 m sprint performance. The H/Q ratio should be considered together with the peak torque values in terms of the assessment of sprinting and jumping performance.

34

Nicolini, Franck Emmanuel, Grzegorz W. Basak, Simona Soverini, Giovanni Martinelli, Michael J. Mauro, Martin C. Müller, Andreas Hochhaus et al. "Allogeneic stem cell transplantation for patients harboring T315I BCR-ABL mutated leukemias". Blood 118, n. 20 (17 novembre 2011): 5697–700. http://dx.doi.org/10.1182/blood-2011-07-367326.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

Abstract (sommario):

Abstract T315I+ Philadelphia chromosome–positive leukemias are inherently resistant to all licensed tyrosine kinase inhibitors, and therapeutic options remain limited. We report the outcome of allogeneic stem cell transplantation in 64 patients with documented BCR-ABLT315I mutations. Median follow-up was 52 months from mutation detection and 26 months from transplantation. At transplantation, 51.5% of patients with chronic myeloid leukemia were in the chronic phase and 4.5% were in advanced phases. Median overall survival after transplantation was 10.3 months (range 5.7 months to not reached [ie, still alive]) for those with chronic myeloid leukemia in the blast phase and 7.4 months (range 1.4 months to not reached [ie, still alive]) for those with Philadelphia chromosome–positive acute lymphoblastic leukemia but has not yet been reached for those in the chronic and accelerated phases of chronic myeloid leukemia. The occurrence of chronic GVHD had a positive impact on overall survival (P = .047). Transplant-related mortality rates were low. Multivariate analysis identified only blast phase at transplantation (hazard ratio 3.68, P = .0011) and unrelated stem cell donor (hazard ratio 2.98, P = .011) as unfavorable factors. We conclude that allogeneic stem cell transplantation represents a valuable therapeutic tool for eligible patients with BCR-ABLT315I mutation, a tool that may or may not be replaced by third-generation tyrosine kinase inhibitors.

35

Rosenthal, Leon, e Raúl Aguilar Roblero. "507 Clinical Impression of Excessive Daytime Sleepiness (EDS) at initial Sleep Medicine (SM) consultation and its clinical correlates". Sleep 44, Supplement_2 (1 maggio 2021): A199—A200. http://dx.doi.org/10.1093/sleep/zsab072.506.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

Abstract (sommario):

Abstract Introduction EDS represents a cardinal symptom in SM. Use of subjective scales are prevalent, which have a modest correlation with the MSLT. While the Clinical Global Impression has been used in research, reports of clinical impression (CI) in medical practice are lacking. We report on the CI of EDS in a convenience sample of patients undergoing initial consultation. Methods Patients reported primary, secondary symptoms and completed the Sleep Wake Activity Inventory (SWAI) prior to Tele-Medicine consultation. A SM physician completed the assessment which included ascertainment of CI of EDS (presence S+ / absence S-). Results There were 39 ♂and 13 ♀. The CI identified 26 patients in each group (S+/S-). Age (52 [14]), BMI (33 [7]), reported time in bed, sleep time, sleep onset latency and # of awakenings did not differ. All identified a primary symptom (S-: 21, S+: 19 reported snoring or a previous Dx of OSA). Sleepiness as a 1ry or 2ry symptom was identified by 0 in the S- and by 13 in the S+ groups. Refreshing quality of sleep differed (χ2 <0.05): un-refreshing sleep was reported by 7 (S-) and by 13 (S+). Naps/week: 0.7 [1.5] and 1.57 [1.5] for the S-, S+ groups respectively (p<0.05). A main effect (p<0.01) was documented on the SWAI. We report on the Sleepiness [SS] and Energy Level [EL] scales (lower scores on the SS reflect higher sleepiness while lower scores on EL denote higher energy). Higher sleepiness (p<0.01) 43 [12] and lower energy levels 24 [6] (p<0.05) were documented on the S+ group (S- 61 [17], and 18 [6] respectively). Available spouse’s Epworth score on 29 patients: S- patients 5.8 [4] and S+ 10.2 [6] (p<0.05). Dx of OSA was identified among all but 1 in the S+ group. Also, Insomnia was diagnosed among 11 (S-) and 19 (S+) patients (p<0.05) despite only 3 and 7 (respectively) identifying it as a presenting symptom. Conclusion While snoring or previous Dx of OSA were prevalent motivations for consultation, sleepiness and insomnia were clinically relevant among a substantial number of patients. Unrefreshing sleep, daytime naps, lower energy, and higher sleepiness were ubiquitous among S+ patients. Support (if any):

36

Tillett, W., V. Navarro-Compán, N. Booth, T. Holzkaemper, J. Hill, E. Lubrano e T. Truer. "AB0548 EFFECTIVENESS OF IXEKIZUMAB IN PATIENTS WITH PSORIATIC ARTHRITIS: RESULTS FROM A REAL-WORLD EUROPEAN SURVEY". Annals of the Rheumatic Diseases 80, Suppl 1 (19 maggio 2021): 1307–8. http://dx.doi.org/10.1136/annrheumdis-2021-eular.2001.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

Abstract (sommario):

Background:Limited real world (RW) data are available for IL-17A blocker ixekizumab (Ixe), approved for psoriatic arthritis (PsA) in EU Feb 2018.Objectives:Describe RW outcomes for PsA patients (pts) receiving Ixe.Methods:Cross-sectional, observational study of PsA pts treated with Ixe in the 2020 Adelphi PsA Plus Program (FR, DE, ES & UK). Rheumatologists recruited the first 6 consecutive consulting Ixe pts and provided demographics, PsA manifestations, clinical measures (66 swollen joint count (SJC), 68 tender joint count (TJC), psoriasis area and severity index [PASI], body surface area [BSA] affected by psoriasis [PsO]), rheumatologist-recorded pt measures (skin/joint pain & fatigue [0-10 numeric rating scales (NRS)], health assessment questionnaire [HAQ-DI]) & prescribed dose. All outcomes recorded for pts with scores available at Ixe initiation (II) & at last assessment (LA).Results:124 rheumatologists provided data for 698 Ixe pts, mean age 49 years (19-79), 48% female, mean BMI 27 (18-44), 56% dermatologist co-managed and mean time diagnosed 6 years (0-35). At Ixe initiation, 78% of pts with known BSA had concomitant mod-sev-PsO defined as BSA≥10% (mean 19.8, n=428) and mean PASI 26.3 (n=164). The predominant PsA phenotype was polyarthritic in 49% (n=345), mono/oligoarthritic in 30% (n=208), axial in 12% (n=81) and enthesitic in 8% (n=55). Previous treatment before Ixe included ≥1 conventional synthetic DMARD (csDMARD) for 71% of pts. Of bio-experienced pts (57%), 40% had received ≥2 biologics. Mean Ixe treatment duration (n=698) 39.4 weeks (wks, 0-170), of which 575 (82%) had received >12 wks of Ixe. 71% of pts received label recommended dose (80mg every 4wks). 52% pts received csDMARD in combination with Ixe. In the RW, Ixe improved TJC, SJC, joint pain, BSA, fatigue and HAQ-DI, Table 1.Table 1.Outcomes for pts receiving Ixe >12weeks (n=575)OverallBSA ≥10% at Ixe initiationMod-sev-PsO physician judgementPredominant mono/oligo arthritisPredominant polyarthritisWith csDMARDWithout csDMARDBSA, n35627025498184188168mean [SD]Ixe initiation (II)19.8 [14.8]24.7 [13.5]23.1 [13.6]17.4 [15.0]20.9 [15.0]21.8 [15.0]17.4 [14.2]Last Assessment (LA)6.6 [7.5]9.3 [8.7]7.9 [7.9]5.0 [6.0]7.6 [8.4]7.3 [7.9]5.9 [7.1]Mean weeks on Ixe43414150414146TJC*, n125728639725669mean [SD, %<5]II12.2 [10.6, 29]14.4 [11.3, 18]12.9 [11.1, 21]6.4 [8.2, 59]15.4 [10.8, 12]13.0 [9.9, 25]11.5 [11.1, 32]LA4.1 [6.4, 77]5.2 [7.7, 71]3.6 [6.3, 80]1.1 [1.4, 97]6.2 [7.7, 64]3.4 [3.9, 73]4.6 [7.8, 80]SJC*, n1458210244846085mean [SD, %<5]II14.8 [13.5, 33]18.8 [14.4, 22]16.3 [13.8, 26]7.2 [8.5, 68]18.2 [13.6, 12]14.5 [12.0, 37]15.1 [14.8, 31]LA4.8 [8.7, 79]7.0 [10.7, 66]5.1 [9.3, 75]0.9 [1.9, 95]6.6 [9.0, 68]3.1 [7.8, 90]5.9 [9.1, 71]Joint pain (NRS 0-10), n575270349166291294281mean [SD]II6.6 [1.7]6.7 [1.7]6.7 [1.7]6.2 [1.8]7.0 [1.5]6.6 [1.7]6.6 [1.6]LA2.7 [1.9]3.0 [2.1]2.8 [2.0]2.1 [1.6]3.0 [2.1]2.8 [1.9]2.5 [1.9]Fatigue (NRS 0-10), n575270349166291294281mean [SD]II5.4 [2.5]5.8 [2.4]5.7 [2.5]4.7 [2.5]5.7 [2.4]5.7 [2.4]5.1 [2.5]LA2.6 [2.1]2.7 [2.1]2.7 [2.2]2.0 [1.9]2.9 [2.2]2.7 [2.1]2.6 [2.1]HAQ DI, n59414210283128mean [SD, %<0.5]II1.8 [0.7, 5]1.9 [0.6, 0]1.8 [0.7, 2]1.9 [0.7, 10]1.8 [0.8, 7]1.9 [0.6, 3]1.7 [0.8, 7]LA0.8 [0.6, 41]0.8 [0.6, 32]0.8 [0.7, 45]0.7 [0.7, 60]0.7 [0.6, 36]0.7 [0.5, 32]0.7 [0.8, 50]*Additional analysis for pts whose fatigue/joint pain rating improved (from ≥4 at Ixe initiation to ≤3 at LA), their mean TJC was 2.7 & SJC 4.3 at LA for fatigue, TJC 1.7 & SJC 2.7 at LA for joint pain.When BSA was not recorded, physician judgement of PsO severity was used. No imputation of missing data.Conclusion:We report RW outcome data amongst pts treated with Ixe including mono/oligo arthritis and a limited sample of enthesitis and dactylitis pts. Our results are consistent with clinical trial populations across disease domains, including an improvement in joint pain.Disclosure of Interests:William Tillett Speakers bureau: AbbVie, Amgen, Celgene, Lilly, Janssen, Novartis, Pfizer Inc. and UCB, Consultant of: AbbVie, Amgen, Celgene, Lilly, Janssen, Novartis, MSD, Pfizer Inc. and UCB, Grant/research support from: AbbVie, Celgene, Eli Lilly & company, Janssen and UCB, Victoria Navarro-Compán Speakers bureau: AbbVie, BMS, Janssen, Eli Lilly & Co, MSD, Novartis, Pfizer, Roche and UCB, Consultant of: AbbVie, BMS, Janssen, Eli Lilly & Co, MSD, Novartis, Pfizer, Roche and UCB, Grant/research support from: AbbVie, BMS, Janssen, Eli Lilly & Co, MSD, Novartis, Pfizer, Roche and UCB, Nicola Booth: None declared., Thorsten Holzkaemper Shareholder of: Eli Lilly & Company, Employee of: Eli Lilly & Company, Julie Hill Shareholder of: Eli Lilly & Company, Employee of: Eli Lilly & Company, Ennio Lubrano Speakers bureau: Alfa-Sigma, Abbvie, Galapagos, Janssen Cilag, Lilly., Consultant of: Alfa-Sigma, Abbvie, Galapagos, Janssen Cilag, Lilly., Tamas Truer Shareholder of: Eli Lilly and Company, Employee of: Eli Lilly and Company.

37

Obando Camino, Maritza, Felipe Matamala e Juan Carlos Carmona Sepúlveda. "Desarrollo morfogénico en micropropagación de semillas de Eucalyptus nitens mejoradas genéticamente". Ciencia & Investigación Forestal 19, n. 2 (12 luglio 2013): 29–38. http://dx.doi.org/10.52904/0718-4646.2013.403.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

Abstract (sommario):

Esta investigación analizó respuestas morfogénicas de semillas de cruzamientos controlados en micropropagación de Eucalyptus nitens. Se utilizó semillas de E. nitens de 6 cruzamientos controlados, para el control se utilizó mezcla familiar. Semillas estériles fueron sembradas en medio MS (1962) modificado, 100 mg/L inositol, 2% sacarosa, 0,7% agar, pH 5,7. Para la inducción de brotes múltiples y elongación utilizó medio MS (1962) modificado, 0.25 mg/L BAP y 0,01 mg/L ANA. El enraizamiento se realizó en medio MS (1962) modificado, con regulador hormonal. Las vitroplántulas fueron mantenidas a 23ºC, fotoperiodo 16/8 h, 25 ?molm-2seg-1. Para 203 clones establecidos de E. nitens, un 69% de ellos desarrollaron brotes múltiples, en 4 ciclos de subcultivo. En las semillas control se diferenciaron 32 clones, donde, un 86,5% desarrolló brotes múltiples. En el cruzamiento A se diferenciaron 26 clones con 100% de multiplicación, para el cruzamiento F se multiplicaron 36% de los clones. De 89 clones diferenciados en semillas de cruzamientos, la cruza B obtuvo un 60% de enraizamiento y un 51% en la cruza E, para 32 clones control solo el 29% enraizaron. Los resultados mostraron que no existieron diferencias significativas en multiplicación, entre las semillas mejoradas y control. Existieron diferencias significativas en enraizamiento entre las cruzas B y E en relación al control. El análisis de resultados se efectuó con ANOVA de una vía con 95% de confianza , Test de Tukey.05 y Statistica versión 6.0. Para graficar se utilizó GraphPad Prism 5

38

Hanhart, Joel, e Itay Chowers. "Evaluation of the Response to Ranibizumab Therapy following Bevacizumab Treatment Failure in Eyes with Diabetic Macular Edema". Case Reports in Ophthalmology 6, n. 1 (10 febbraio 2015): 44–50. http://dx.doi.org/10.1159/000375230.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

Abstract (sommario):

Background/Aims: Bevacizumab and ranibizumab are routinely used to treat diabetic macular edema (DME). We aim to evaluate the usefulness of switching to ranibizumab therapy following bevacizumab treatment failure in eyes with DME. Methods: We performed a retrospective analysis of a consecutive group of patients with DME who received ranibizumab injections following the failure of bevacizumab injections. The injections were delivered following a pro re nata protocol every 4-6 weeks. The data collected included demographics, systemic and ophthalmic findings, as well as the central subfield thickness according to spectral-domain OCT. Results: Eight eyes (5 patients) were included in the study. The median number of bevacizumab injections prior to the switch to ranibizumab was 4, and the median number of ranibizumab injections during the study was 2. The mean follow-up period was 541 ± 258 days. The mean central retinal thickness (CRT) (±SEM) was 539 ± 75 μm before the initiation of bevacizumab treatment, and 524 ± 43 μm after the last bevacizumab injection (p = 0.7). It reduced to 325 ± 26 μm following the ranibizumab injections (p = 0.0063). The best-corrected visual acuity (BCVA) improved in 4 eyes and remained stable in 4 eyes following the ranibizumab injections. Conclusion: A ranibizumab therapy was effective in reducing the CRT in eyes that failed bevacizumab therapy. A BCVA improvement can also occur in these eyes. Switching between anti-vascular endothelial growth factor compounds may be beneficial in eyes with DME.

39

Cabri, L. J., A. M. McDonald, C. J. Stanley, N. S. Rudashevsky, G. Poirier, H. R. Wilhelmij, W. Zhe e V. N. Rudashevsky. "Palladosilicide, Pd2Si, a new mineral from the Kapalagulu Intrusion, Western Tanzania and the Bushveld Complex, South Africa". Mineralogical Magazine 79, n. 2 (aprile 2015): 295–307. http://dx.doi.org/10.1180/minmag.2015.079.2.08.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

Abstract (sommario):

AbstractPalladosilicide, Pd2Si, is a new mineral (IMA 2014-080) discovered in chromite-rich samples from the Kapalagulu intrusion, western Tanzania (30°03′51′′E 5°53′16′′S and 30°05′37′′E 5°54′26′′S) and from the UG-2 chromitite, Bushveld complex, South Africa. A total of 13 grains of palladosilicide, ranging in size from 0.7 to 39.1 μm (equivalent circle diameters), were found. Synthetic Pd2Si is hexagonal, space group P62m, with a = 6.496(5), c = 3.433(4) Å, V = 125.5(1) Å3, c:a = 0.529 with Z = 3. The strongest lines calculated from the powder pattern (Anderko and Schubert, 1953) are [d in Å (I) (hkl)] 2.3658 100 (111); 2.1263 37 (120); 2.1808 34 (021); 3.240 20 (110); 1.8752 19 (030); 1.7265 12 (002); 1.3403 11 (122); 1.2089 10 (231). The calculated density for three analyses varies from 9.562 to 9.753 g cm–3. Palladosilicide is considered to be equivalent to synthetic Pd2Si based on results from electron backscattered diffraction analyses. Reflectance data in air for the four Commission on Ore Mineralogy wavelengths are [λ nm, R1 (%) R2 (%)] 470 49.6 52.7; 546 51.2 53.8; 589 51.6 53.7; 650 51.7 53.3 and the mineral is bright creamy white against chromite, weakly bireflectant and displays no discernible pleochroism or twinning. It is weakly anisotropic, has weak extinction and rotation tints in shades of blue and olive green. Electron probe microanalyses of palladosilicide yield a simplified formula of Pd2Si.

40

Lazow, Margot, Andrew Trout, Christine Fuller, Jaime Reuss, Brian Turpin, Joseph Stanek, Sara Szabo e Ralph Salloum. "BIOM-42. IMMUNOHISTOCHEMICAL ASSESSMENT OF MEMBRANOUS SOMATOSTATIN TYPE 2A RECEPTOR (SST2A) EXPRESSION ACROSS HIGH-RISK PEDIATRIC CENTRAL NERVOUS SYSTEM (CNS) TUMORS". Neuro-Oncology 23, Supplement_6 (2 novembre 2021): vi20. http://dx.doi.org/10.1093/neuonc/noab196.073.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

Abstract (sommario):

Abstract INTRODUCTION 77Lu-DOTATATE, a radionuclide therapy which binds SST2A, has demonstrated efficacy in neuroendocrine tumors and evidence of CNS penetration, supporting potential expansion within pediatric neuro-oncology. Understanding the prevalence of SST2A expression across pediatric CNS tumors is essential to identify patients who may benefit from somatostatin receptor-targeted therapy and to further elucidate the oncogenic role of SST2A. METHODS SST2A immunohistochemistry (IHC) was performed on tumor specimens and interpreted by two experienced pathologists (blinded), utilizing semi-quantitative scoring of membranous expression within viable tumor. Immunoreactive cell percentage was visually scored as 0 (none), 1 (< 10%), 2 (10-50%), 3 (51-80%), or 4 (>80%). Staining intensity was scored as 0 (none), 1 (weak), 2 (moderate), or 3 (strong). Combined scores for each specimen were calculated by multiplying percent immunoreactivity and staining intensity values (range=0-12). RESULTS A total of 117 tumor samples from 113 patients were analyzed. Significant differences in SST2A IHC scores were observed across histopathologic diagnoses, with consistently high scores in medulloblastoma (mean±SD=7.6±3.6 [n=36]) and meningioma (5.7±3.4 [n=15]), compared to minimal or absent expression in ATRT (0.3±0.6 [n=3]), ETMR (1.0±0 [n=3]), ependymoma (grades I-III; 0.2±0.7 [n=26]), and high-grade glioma (grades III-IV; 0.4±0.7 [n=22]). Pineoblastoma (3.8±1.5 [n=4]) and other embryonal tumors (2.3±3.8 [n=8]) exhibited intermediate, variable expression. Among expressors, there was no association between SST2A IHC score and patient age, sex, presence of metastases, likelihood of relapse, or prior treatment. In a subset of paired primary and recurrent specimens from 3 patients, SST2A IHC scores remained largely unchanged. Among medulloblastomas, SST2A IHC scores were higher in non-SHH (8.6±3.2) than SHH (5.0±3.3) molecular subgroups (p=0.033). CONCLUSIONS High membranous SST2A expression was demonstrated in medulloblastoma, meningioma, and some rarer embryonal tumors with potential diagnostic, biologic, and therapeutic implications. Somatostatin receptor-targeted therapy such as 177Lu-DOTATATE deserves further investigation in these highly SST2A-expressing pediatric CNS tumors.

41

Goodman, Elizabeth K., Yimei Li, Alix E. Seif, Julie Fitzgerald, Yuan-Shung Huang, Rochelle Bagatell, Brian T. Fisher e Richard Aplenc. "Treatment Toxicity and Supportive Care Utilization in Children with Down Syndrome and Acute Lymphoid Leukemia at Free-Standing Pediatric Hospitals in the United States". Blood 124, n. 21 (6 dicembre 2014): 553. http://dx.doi.org/10.1182/blood.v124.21.553.553.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

Abstract (sommario):

Abstract Introduction: Children with Down syndrome (DS) and acute lymphoid leukemia (ALL) have inferior outcomes due to increased treatment-related toxicity. In 2005 and 2006, multiple clinical trial protocols were modified to increase supportive care measures for these children; however, national supportive care utilization patterns for these patients have not been subsequently evaluated. Methods: A validated retrospective cohort of pediatric patients with ALL admitted from 1999 to 2011 was assembled from the Pediatric Health Information System (PHIS) database to examine organ toxicity, sepsis, and resource utilization in children with and without DS. A sub-analysis of mortality in children with DS ALL before and after the 2006 supportive care recommendation was also conducted. Results: 10699 patients with ALL were identified; 298 of these children had DS ALL (2.8%). Children with DS ALL had a significantly higher percentage of patients who were female (52% vs. 44%, p = 0.003), white (83% vs. 75%, p = 0.005), publically insured (48% vs. 38%, p = 0.002), and who had a congenital cardiac abnormality (26% vs. 2%, p < 0.0001). DS was associated with an increased risk of cardiovascular failure (OR 2.0, 95% CI 1.6-2.7), respiratory failure (OR 2.1, 95% CI: 1.6-2.9) and sepsis (OR 1.8, 95% CI: 1.4-2.4) in adjusted analyses (Table 1). Children with DS ALL had significantly greater utilization of antibiotics indicated for gram-positive infections, quinolones, azoles, supplemental oxygen, and ventilation, as well as significantly less utilization of opiate and non-opiate analgesics, PCAs, and antiemetics compared to children with non-DS ALL. Cardiac failure and sepsis rates were decreased in all children diagnosed after 2006 (OR 0.8, CI: 0.8-0.9, and OR 0.7, CI: 0.6-0.7, respectively). Children with DS ALL demonstrated a non-significant decrease in mortality after the 2006 guideline implementation (6.6% to 2.8%, p=0.116). Conclusion: In conclusion, children with DS ALL have significantly increased cardiac, respiratory, and infectious toxicity. The elevated antibiotic and antifungal usage in children with DS ALL and trend towards mortality decrease may suggest successful implementation of supportive care measures; however, decreased analgesic and antiemetic use may suggest other unmet supportive care needs in these patients. Table Table 1. Adjusted analyses of organ failure by Down syndrome status, demographics, congenital cardiac defects, and year of admission.CardiovascularFailure OR (95% CI)RespiratoryFailure OR (95% CI)Sepsis OR (95% CI)NeurologicFailure OR (95% CI)LiverFailure OR (95% CI)Down syndrome2.0 (1.6-2.7)***2.1 (1.6-2.9)***1.8 (1.4-2.4)***3.4 (1.9-6.2)***1.4 (1.0-1.9)*Age< 1 yr.4.5 (3.5-5.8)***7.4 (5.7-9.7)***8.3 (4.9-8.2)***1.4 (0.6-3.3)1.9 (1.4-2.5)***³ 1 yr. and < 5 yrs.0.7 (0.6-0.7)***0.7 (0.6-0.8)***0.9 (0.7-1.0)*0.4 (0.3-0.7)**1.0 (0.8-1.1)³ 5 yrs. and < 10 yrs.-----³ 10 yrs. and < 15 yrs.2.2 (1.9-2.5)***1.8 (1.5-2.1)***1.7 (1.4-1.9)***2.1 (1.4-3.2)**1.4 (1.2-1.6)***³ 15 yrs.2.4 (2.0-2.8)***2.2 (1.8-2.7)***2.0 (1.6-2.3)***2.7 (1.7-1.2)***1.7 (1.4-2.0)***RaceNon-Whitea0.9 (0.8-1.0)1.1 (0.9-1.2)1.0 (0.9-1.2)1.4 (1.0-2.0)*0.8 (0.7-0.9)**White----InsurancePublicb1.3 (1.1-1.4)***1.2 (1.1-1.4)**1.5 (1.3-1.6)***1.3 (0.9-1.9)1.0 (0.9-1.1)Otherc1.2 (1.0-1.3)*0.8 (0.7-1.0)*1.0 (0.9-1.1)1.5 (1.0-2.3)*1.0 (0.8-1.1)Private----GenderFemale1.1 (1.0-1.2)*1.0 (0.9-1.1)1.2 (1.1-1.3)**1.0 (0.7-1.3)1.1 (1.0-1.2)Male----Congenital Cardiac Defectd1.6 (1.2-2.1)**1.5 (1.1-2.1)**1.3 (0.9-1.7)1.7 (0.8-3.4)1.1 (0.8-1.6)Diagnosis in 2006-20110.8 (0.8-0.9)**1.0 (0.9-1.2)0.7 (0.6-0.7)***0.8 (0.6-1.0)1.0 (0.9-1.1)a Non-white includes Black, Asian/Pacific Islander, American Indian, Other, and Unknown. bPublic includes Medicaid, Medicare, other government, and Title V. cOther includes Self-pay, Other, and Unknown. d Congenital cardiac defect was defined by ICD-9 codes as described in supplemental table 1. *** p < 0.001; ** p < 0.01; * p < 0.05. Disclosures No relevant conflicts of interest to declare.

42

Ingle, J., D. Tu, L. Shepherd, M. Palmer, J. Pater e P. Goss. "NCIC CTG MA.17: Intent to treat analysis (ITT) of randomized patients after a median follow-up of 54 months". Journal of Clinical Oncology 24, n. 18_suppl (20 giugno 2006): 549. http://dx.doi.org/10.1200/jco.2006.24.18_suppl.549.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

Abstract (sommario):

549 Background: MA.17 evaluated letrozole (LET) or placebo (PLAC) after 5 years of tamoxifen (Tam) and showed [median follow-up 30 months (mos)] significant improvement in disease-free survival (DFS) for LET [hazard ratio (HR) 0.57, p = 0.00008]. The trial was unblinded and PLAC patients (pts) were offered LET. An ITT analysis of all outcomes, before and after unblinding, based on the original randomization was performed. Methods: A stratified log-rank test was used to compare DFS, distant (D)DFS, overall survival (OS) and incidence of contra-lateral breast cancer (CBC). The Cox regression model used baseline stratification variables and two prespecified factors, menopausal status at the start of Tam and time on Tam. Subgroup analyses for DFS and OS were performed for the two prespecified subsets. All p-values were two-sided Results: 5187 pts were randomized at baseline and, at unblinding, 1655 of 2268 PLAC pts accepted LET. At median follow-up of 54 mos (range,16–86) 363 recurrences or CBC’s (144 LET and 219 PLAC) occurred; 118 LET and 176 PLAC pts had recurrent disease and 26 LET and 43 PLAC pts had CBC. 4 year DFS was 94.3% (LET) and 91.4% (PLAC) (HR 0.64; 95% CI, 0.52 - 0.79; p = 0.00002). Corresponding 4 year DDFS was 96.2% and 94.9% (HR 0.76; 0.58–0.99; p = 0.041). 4 year OS was 95.0% (LET) and 95.1% (PLAC) (HR 1.00; 0.78–1.28; p = 0.99). LET was equally effective in node +ve and -ve pts (i.e., similar HRs) in DFS. OS was not significantly different for LET and PLAC in any subgroup. The annual rate of CBC was 0.29% LET (0.18–0.40) and 0.47% PLAC (0.34–0.61); HR 0.61 (0.38–0.98) p = 0.037. 255 pts had died as of the data cut-off (128 LET and 127 PLAC). Conclusions: In this ITT analysis, pts originally randomized to LET within 3 months of stopping Tam did better than PLAC pts in DFS, DDFS and CBC, despite 73% of PLAC pts crossing to LET after unblinding. This highlights the strong beneficial effect of extended adjuvant therapy with LET. [Table: see text]

43

Wanick, Fabiana Braga França, Tullia Cuzzi Teichner, Rosane Silva, Mônica Maria Ferreira Magnanini e Lucia Maria Soares de Azevedo. "Carcinoma epidermoide do pênis: estudo clínico-patológico de 34 casos". Anais Brasileiros de Dermatologia 86, n. 6 (dicembre 2011): 1082–91. http://dx.doi.org/10.1590/s0365-05962011000600004.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

Abstract (sommario):

FUNDAMENTOS: No Brasil, a incidência do câncer do pênis é de 8,3 casos/100.000 habitantes, contrastando com 0,7 na Europa e nos Estados Unidos. Em 95% dos casos, trata-se do carcinoma epidermoide. Em geral, é diagnosticado tardiamente. OBJETIVOS: Descrever as características clínico-patológicas do carcinoma epidermoide do pênis, registradas no Hospital entre 1978 e 2004. MÉTODOS: Estudo observacional transversal. Incluíram-se os casos de carcinoma epidermoide do pênis, confirmados histologicamente. Avaliaram-se, pessoalmente, os pacientes que atenderam à convocação para o estudo, enquanto os demais tiveram seus dados pesquisados nos prontuários médicos. RESULTADOS: Registraram-se 34 pacientes com carcinoma epidermoide do pênis: 8 in situ e 26 invasivos, com idade média de 54,7 12,5 anos, respectivamente. A± 22,4 e 64,7 ±, a glande foi acometida em 91,1% dos casos e o prepúcio, em 41,1%. Os carcinomas epidermoides in situ exibiam pápulas ou eritema e erosão, geralmente menores do que 2 cm. Os invasivos mostravam úlceras e/ou vegetações, geralmente únicas, e maiores do que 2 cm. Dos CE invasivos, 80,8% eram bem diferenciados; metade encontrava-se no estágio I TNM e o restante, do II ao IV; 16 pacientes tiveram o pênis amputado e 3 faleceram. CONCLUSÕES: O câncer do pênis é raro, acomete adultos de todas as faixas etárias e o tratamento pode ser agressivo. O aspecto clínico inespecífico das lesões iniciais, o insuficiente treinamento médico em lesões dermatológicas e a carência de rotinas de investigação diagnóstica, tratamento e acompanhamento destes casos contribuem para o mau prognóstico desta neoplasia.

44

Zada, Gabriel, Paul G. Pagnini, Cheng Yu, Kelly T. Erickson, Jonah Hirschbein, Vladimir Zelman e Michael L. J. Apuzzo. "Long-term Outcomes and Patterns of Tumor Progression After Gamma Knife Radiosurgery for Benign Meningiomas". Neurosurgery 67, n. 2 (1 agosto 2010): 322–29. http://dx.doi.org/10.1227/01.neu.0000371974.88873.15.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

Abstract (sommario):

Abstract OBJECT To characterize the timing and patterns of long-term treatment failure after Gamma Knife radiosurgery (GKRS) for benign meningiomas. METHODS Data were retrospectively reviewed in 116 patients who underwent 136 GKRS treatments for benign intracranial meningiomas from 1996 to 2004. Patients with atypical or malignant meningiomas were excluded. Surgical resection preceded GKRS in 72 patients (62%). The median tumor volume was 3.4 cm3, and the median prescription dose to the 50% isodose line was 16 Gy. RESULTS The median follow-up time was 75 months (range, 4–146 months). Overall tumor control was achieved in 128 of 136 lesions (94%), of which tumor size was stable in 68% and decreased in 26%. Seven patients experienced disease progression in 8 tumors, occurring at a mean time of 90 months. The overall 5-year and 10-year actuarial tumor control rate was 98.9% and 84%, respectively. Characteristics corresponding to tumor progression included insufficient tumor coverage (98% vs 93%, P = .007), cavernous sinus lesions, and meningiomatosis. Complications after GKRS developed in 8% of patients, in whom the mean tumor volume was nearly double that in patients with no adverse effects (11 vs 5.7 cm3, P = .003). CONCLUSIONS GKRS demonstrates excellent long-term tumor control in the management of benign meningiomas. Tumor progression occurred at a mean time of 7.5 years after GKRS, reinforcing the need for long-term surveillance despite initial tumor control. Treatment failure was related to undercoverage of lesions in the majority of cases, with the remainder demonstrating evidence of abnormal tumor biology.

45

FANG, Zhi You, Rodel LEANO e Thomas H. MARWICK. "Relationship between longitudinal and radial contractility in subclinical diabetic heart disease". Clinical Science 106, n. 1 (1 gennaio 2004): 53–60. http://dx.doi.org/10.1042/cs20030153.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

Abstract (sommario):

Subclinical left ventricular (LV) dysfunction may be identified by reduced longitudinal contraction. We sought to define the effects of subclinical LV dysfunction on radial contractility in 53 patients with diabetes mellitus with no LV hypertrophy, normal ejection fraction and no ischaemia as assessed by dobutamine echocardiography, in comparison with age-matched controls. Radial peak myocardial systolic velocity (Sm) and early diastolic velocity (Em), strain and strain rate were measured in the mid-posterior and mid-anteroseptal walls in parasternal views and each variable was averaged for individual patients (radial contractility). These variables were also measured in the mid-posterior and mid-anteroseptal walls in the apical long-axis view and each variable was averaged for individual patients (longitudinal contractility). Mean radial Sm, strain and strain rate were significantly increased in diabetic patients (2.9±0.6 cm/s, 28±5% and 1.8±0.4 s-1 respectively) compared with controls (2.4±0.7 cm/s, 23±4% and 1.6±0.3 s-1 respectively; all P<0.001), but there was no difference in Em (3.3±1.2 compared with 3.1±1.1 cm/s, P=not significant). In contrast, longitudinal Sm, Em, strain and strain rate were significantly lower in diabetic patients (3.6±1.1 cm/s, 4.3±1.6 cm/s, 21±4% and 1.6±0.3 s-1 respectively) than in controls (4.3±1.0 cm/s, 5.7±2.3 cm/s, 26±4% and 1.9±0.3 s-1 respectively; all P ⩽ 0.001). Thus radial contractility appears to compensate for reduced longitudinal contractility in subclinical LV dysfunction occurring in the absence of ischaemia or LV hypertrophy.

46

Miserocchi, G., D. Negrini, M. Del Fabbro e D. Venturoli. "Pulmonary interstitial pressure in intact in situ lung: transition to interstitial edema". Journal of Applied Physiology 74, n. 3 (1 marzo 1993): 1171–77. http://dx.doi.org/10.1152/jappl.1993.74.3.1171.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

Abstract (sommario):

In anesthetized rabbits (n = 25) subject to slow intravenous saline loading (0.4 ml.min-1.kg-1) for 3 h, we measured pulmonary interstitial pressure (Pip) in intact in situ lungs with glass micropipettes inserted directly into the lung parenchyma via a "pleural window." Measurements were done in apneic animals at the end-expiratory volume with O2 delivered in the trachea. Pip was -10 +/- 1.5 (SD) cmH2O in control and increased to 0.6 +/- 3.8 and 5.7 +/- 3.3 cmH2O at 66 and 180 min, respectively. The wet-to-dry weight ratio (W/D) of the lung was 5.04 +/- 0.2 in the control group and 5.34 +/- 0.7 at 180 min (+6%); the corresponding W/D for intercostal muscles were 3.25 +/- 0.03 and 4.19 +/- 0.5 (+28%). Pulmonary interstitial compliance was 0.47 ml.mmHg-1.100 g wet wt-1. Pulmonary arterial and left atrial pressures were 18.4 +/- 2 and 3 +/- 1 cmH2O in control and increased to 19.5 +/- 2.9 and 4.6 +/- 1.7 cmH2O at 180 min, respectively. Aortic flow (cardiac output) increased from 103 +/- 35 to 131 +/- 26 ml/min; pulmonary resistance fell from 0.17 +/- 0.06 to 0.14 +/- 0.05 cmH2O.min.ml-1 (-18%), suggesting that the increase in Pip did not limit blood flow. The pulmonary capillary-to-interstitium filtration pressure gradient decreased sharply from a control value of 10 cmH2O to 0 cmH2O within 60 min because of the increase in Pip and remained unchanged for < or = 180 min. Data suggest that the pulmonary interstitial matrix can withstand fluid pressures above atmospheric, preventing the development of pulmonary alveolar flooding.

47

Lee, Jin Soo, Vera Hirsh, Keunchil Park, Shukui Qin, Cesar R. Blajman, Reury-Perng Perng, Yuh-Min Chen, Laura Emerson, Peter Langmuir e Christian Manegold. "Vandetanib Versus Placebo in Patients With Advanced Non–Small-Cell Lung Cancer After Prior Therapy With an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor: A Randomized, Double-Blind Phase III Trial (ZEPHYR)". Journal of Clinical Oncology 30, n. 10 (1 aprile 2012): 1114–21. http://dx.doi.org/10.1200/jco.2011.36.1709.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

Abstract (sommario):

Purpose Vandetanib is a once-daily oral inhibitor of vascular endothelial growth factor receptor, epidermal growth factor receptor (EGFR), and RET signaling. This placebo-controlled trial assessed whether vandetanib conferred an overall survival benefit in patients with advanced non–small-cell lung cancer (NSCLC) after prior treatment with an EGFR tyrosine kinase inhibitor and one or two chemotherapy regimens. Patients and Methods Eligible patients were randomly assigned 2:1 to receive vandetanib 300 mg/d or placebo until disease progression or unacceptable toxicity. The primary objective was to compare the outcomes between the two arms with respect to overall survival. Results Overall, 924 patients received vandetanib (n = 617) or placebo (n = 307). No significant increase in overall survival was detected in the vandetanib cohort compared with placebo (hazard ratio = 0.95; 95.2% CI, 0.81 to 1.11; P = .527); median overall survival was 8.5 months versus 7.8 months for vandetanib and placebo patients, respectively. Statistically significant advantages favoring vandetanib were observed for progression-free survival (hazard ratio = 0.63; P < .001) and objective response rate (2.6% v 0.7%; P = .028). Postprogression therapy was balanced across the cohorts in both number and type. Adverse events were generally consistent with previous NSCLC studies of vandetanib 300 mg; common events occurring with a greater frequency in the vandetanib arm versus placebo included diarrhea (46% v 11%), rash (42% v 11%), and hypertension (26% v 3%). Conclusion The study did not demonstrate an overall survival benefit for vandetanib versus placebo. There was a higher incidence of some adverse events with vandetanib.

48

Siegert, Paul, Fabian Plachel, Doruk Akgün, Alexander D. J. Baur, Eva Schulz, Alexander Auffarth, Mark Tauber e Philipp Moroder. "Comparison of Structural Subscapularis Integrity After Latarjet Procedure Versus Iliac Crest Bone Graft Transfer". Orthopaedic Journal of Sports Medicine 8, n. 10 (1 ottobre 2020): 232596712095800. http://dx.doi.org/10.1177/2325967120958007.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

Abstract (sommario):

Background: Although clinical outcome scores are comparable after coracoid transfer procedure (Latarjet) and iliac crest bone graft transfer (ICBGT) for anterior shoulder instability with glenoid bone loss, a significant decrease in internal rotation capacity has been reported for the Latarjet procedure. Hypothesis: The subscapularis (SSC) musculotendinous integrity will be less compromised by ICBGT than by the Latarjet procedure. Study Design: Cohort study; Level of evidence, 3. Methods: We retrospectively analyzed pre- and postoperative computed tomography (CT) scans at short-term follow-up of 52 patients (26 Latarjet, 26 ICBGT) previously assessed in a prospective randomized controlled trial. Measurements included the preoperative glenoid defect area and graft area protruding the glenoid rim at follow-up and tendon thickness assessed through SSC and infraspinatus (ISP) ratios. Fatty muscle infiltration was graded according to Goutallier, quantified with muscle attenuation in Hounsfield units, and additionally calculated as percentages. We measured 3 angles to describe rerouting of the SSC musculotendinous unit around the bone grafts. Results: SSC fatty muscle infiltration was 2.0% ± 2.2% in the Latarjet group versus 2.4% ± 2.2% in ICBGT ( P = .546) preoperatively and showed significantly higher values in the Latarjet group at follow-up (5.3% ± 4.5% vs 2.3% ± 1.7%; P = .001). In total, 4 patients (15.4%) in the Latarjet group showed a progression from grade 0 to grade 1 at follow-up, whereas no changes in the ICBGT group were noted. The measured rerouting angle of the SSC muscle was significantly increased in the Latarjet group (11.8° ± 2.1°) compared with ICBGT (7.5° ± 1.3°; P < .001) at follow-up, with a significant positive correlation between this angle and fatty muscle infiltration ( R = 0.447; P = .008). Ratios of SSC/ISP tendon thickness were 1.03 ± 0.3 in the Latarjet group versus 0.97 ± 0.3 ( P = .383) in ICBGT preoperatively and showed significantly lower ratios in the Latarjet group (0.7 ± 0.3 vs 1.0 ± 0.2; P < .001) at follow-up. Conclusion: Although clinical outcome scores after anterior shoulder stabilization with a Latarjet procedure and ICBGT are comparable, this study shows that the described decline in internal rotation capacity after Latarjet procedure has a radiographic structural correlate in terms of marked thinning and rerouting of the SSC tendon as well as slight fatty degeneration of the muscle.

49

Atkinson, Bradley J., Sarathi Kalra, Xuemei Wang, Nizar M. Tannir e Eric Jonasch. "A single-center retrospective review of outcomes associated with sunitinib alternative schedule compared to traditional schedule." Journal of Clinical Oncology 31, n. 6_suppl (20 febbraio 2013): 381. http://dx.doi.org/10.1200/jco.2013.31.6_suppl.381.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

Abstract (sommario):

381 Background: Sunitinib is a front-line therapy for metastatic renal cell cancer (mRCC). Recommended dose is 50 mg daily; 28 days (d) on/14 d off (traditional schedule; TS). Sunitinib is associated with several adverse events (AEs). An ideal treatment modification algorithm is not known. We sought to identify (1) common AEs, (2) alternative schedules (AS) that maintained dose intensity while decreasing AEs, and (3) the impact of AS on outcomes. Methods: Single-center retrospective review of mRCC pts performed from January 26, 2006 to March 1, 2011. Pts > 18 years of age with mRCC who received first-line antiangiogenic therapy with sunitinib were eligible. A subset of pts were switched at first intolerable AE from TS to a 14 d/7 d, or further adjusted to 7 d /3 d, or other AS. Control group underwent standard dose reduction. Pt characteristics including demographics, disease status, laboratory data, AEs, AS, and treatment outcomes were analyzed. Results: 186 eligible pts were identified. At baseline, 87% received sunitinib 50 mg and 88% were on TS. 99 pts (53%) continued TS and 87 pts (47%) were switched to AS. Baseline characteristics were similar. Median age was 61 yrs; by MSKCC criteria 5% were good, 50% intermediate, and 45% poor prognosis. Pts had median 2 visceral mets and 42% had primary tumor in place. AEs included fatigue (47%), diarrhea (24%), and hand-foot syndrome (26%). Median time to AS was 126 d with 14 d/7 d the most common (82%). Median time on treatment was 14.9 months (mo) (95% CI:10.2 – 17.0 mo) in AS pts vs. 4.2 mo (95% CI: 3.6 – 5.7 mo), respectively (p < 0.0001). Median OS was 32.9 mo (95% CI:28.3-54.1 mo) vs. 18.5 mo (95% CI: 10.3-21.5 mo), respectively (p = 0.0001). ECOG PS > 2 (HR 3.9), elevated LDH (HR 2.04), and > 2 mets (HR 1.79) were associated with decreased OS. MSKCC intermediate vs. poor (HR 0.57) and AS (HR 0.54) were associated with improved OS by multivariate regression analysis (p < 0.05). Conclusions: In our cohort study, AS sunitinib significantly prolonged outcomes and was predictive of OS. Prospective investigations of alternate dosing schemas are warranted.

50

Atkinson, Bradley J., Sarathi Kalra, Xuemei Wang, Tharakeswara Bathala, John Perpich, Paul Gettys Corn, Nizar M. Tannir e Eric Jonasch. "Outcomes associated with sunitinib alternative schedule compared to traditional schedule: a single-center experience." Journal of Clinical Oncology 31, n. 15_suppl (20 maggio 2013): e15611-e15611. http://dx.doi.org/10.1200/jco.2013.31.15_suppl.e15611.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

Abstract (sommario):

e15611 Background: Sunitinib is a front-line therapy for metastatic renal cell cancer (mRCC). Recommended dose is 50 mg daily; 28 days (d) on/14 d off (traditional schedule; TS). Sunitinib is associated with several adverse events (AEs). An ideal treatment modification algorithm is not known. We sought to identify 1) common AEs, 2) alternative schedules (AS) that maintained dose intensity while decreasing AEs, and 3) the impact of AS on outcomes. Methods: Single-center retrospective review of mRCC pts performed from 1/26/06 to 3/1/11. Pts > 18 years of age with mRCC who received first-line antiangiogenic therapy with sunitinib were eligible. A subset of pts were switched at first intolerable AE from TS to a 14 d/7 d, or further adjusted to 7 d /3 d, or other AS. Control group underwent standard dose reduction. Pt characteristics including demographics, disease status, laboratory data, AEs, AS, and treatment outcomes were analyzed. Results: 186 eligible pts were identified. At baseline, 87% received sunitinib 50 mg and 88% were on TS. 99 pts (53%) continued TS and 87 pts (47%) were switched to AS. Baseline characteristics were similar. Median age was 61 yrs; by MSKCC criteria 5% were good, 50% intermediate, and 45% poor prognosis. Pts had median 2 visceral mets and 42% had primary tumor in place. AEs included fatigue (47%), diarrhea (24%), and hand-foot syndrome (26%). Median time to AS was 126 d with 14 d/7 d the most common (82%). Median time on treatment was 14.9 months (mo) (95% CI:10.2 – 17.0 mo) in AS pts vs 4.2 mo (95% CI: 3.6 – 5.7 mo), respectively (p < 0.0001). Median OS was 32.9 mo (95% CI:28.3-54.1 mo) vs 18.5 mo (95% CI: 10.3-21.5 mo), respectively (p = 0.0001). ECOG PS > 2 (HR 3.9), elevated LDH (HR 2.04), and > 2 mets (HR 1.79) were associated with decreased OS. MSKCC intermediate vs poor (HR 0.57) and AS (HR 0.54) were associated with improved OS by multivariate regression analysis (p < 0.05). Conclusions: In our cohort study, AS sunitinib significantly prolonged time on treatment and was predictive of OS. Prospective investigations of alternate dosing schemas are warranted.

Articoli di riviste sul tema "547.057 26"

Cita una fonte nei formati APA, MLA, Chicago, Harvard e in molti altri stili